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Abstract 
Natural (n) T regulatory (Treg) cells generated in the thymus are essential throughout life for 
the maintenance of T cell homeostasis and prevention of autoimmunity. T cell receptor 
(TCR)/CD28-mediated activation of Nuclear Factor Kappa-light-chain-enhancer of activated 
B cells (NFB) and Jun N-terminal kinase (JNK) pathways is known to play a key role in 
nTreg development but many of the predicted molecular interactions are based on 
extrapolations from non-Treg cell TCR stimulation with non-physiological ligands. For the 
first time, this work provides strong genetic evidence of a scaffold function for the Caspase 
Recruitment Domain (CARD) of the TCR signalling protein CARD-MAGUK1 (CARMA1) 
in nTreg development in vivo. I report two, new, N-ethyl-N-nitrosourea (ENU)-derived 
mutant mice, Vulpo and Zerda, with a profound block in the development of nTregs in the 
thymus as well as impaired inducible (i) Treg differentiation in the periphery. Despite 
independent heritage, both mutants harbour different point mutations in the CARD of the 
CARMA1 protein. vulpo and zerda mutations do not affect expression levels of CARMA1 but 
still impair signalling through the TCR due to defective downstream B cell CLL/Lymphoma 
10 (Bcl-10) protein recruitment by the mutated CARD of CARMA1. Phenotypic differences 
observed between Vulpo and Zerda mutants suggest a role for the CARD of CARMA1 
independent of Bcl-10 activation of downstream pathways. I conclude that this forward 
genetic approach demonstrates a critical role for the CARD function of CARMA1 in Treg 
development in vivo.   
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1.1 Adaptive Immunity 
Defence against microbes is mediated by the early reactions of innate, or natural, immunity 
and the later responses of adaptive, or acquired, immunity. The principle components of 
innate immunity are physical and chemical barriers, such as epithelia and antimicrobial 
substances produced at epithelial surfaces; phagocytic neutrophil and macrophage cells, as 
well as natural killer cells; blood proteins, including members of the complement system and 
other mediators of inflammation; and cytokine proteins that regulate and coordinate the 
activities of the cells of innate immunity. Innate immunity is phylogenetically the oldest 
system of host defence but many pathogenic microbes evolved to resist innate immunity and 
so their elimination required the more powerful mechanisms of adaptive immunity. In contrast 
to innate immunity, adaptive immunity is stimulated by exposure to infectious agents. It is 
exquisitely specific for distinct molecules, and has the capacity for memory which enables it 
to increase its magnitude and defensive capabilities with each successive exposure to a 
particular microbe. Lymphocytes are the only cells capable of specifically recognising 
antigens and are thus the principle component of the adaptive immune system.  
 
Adaptive immune responses consist of distinct phases, the first three being the recognition of 
antigen, the activation of lymphocytes, and the elimination of antigen (the effector phase). 
The response contracts as antigen-stimulated lymphocytes die by apoptosis, restoring 
homeostasis, and the antigen-specific cells that survive are responsible for memory. These 
phases are illustrated in Figure 1.1-1.  
 
 
 
 
  
 
20 
 
 
 
 
Figure 1.1-1: Phases of the adaptive immune response.  
Adaptive immune responses consist of distinct phases, the first three being the recognition of 
antigen, the activation of lymphocytes, and the elimination of antigen (the effector phase). The 
response contracts as antigen-stimulated lymphocytes die by apoptosis, restoring 
homeostasis, and the antigen-specific cells that survive are responsible for memory. The y-
axis represents an arbitrary measure of the magnitude of the response.  
[Taken from: Cellular and Molecular Immunology, 6
th
 edition. Abbas, Lichtman and Pillai. 
2007. Philadelphia: Saunders Elsevier, p. 14.]  
 
  
  
 
21 
The adaptive immune response is itself made up of humoral immunity, mediated by B 
lymphocytes and secreted antibody products, and cell-mediated immunity which is mediated 
by T lymphocytes and their products, such as cytokines. In general, humoral immunity 
functions in defence against extracellular microbes and cell-mediated immunity is important 
for defence against intracellular microbes. The principle of a phased response to antigenic 
exposure (Figure 1.1-1) applies to both humoral and cell-mediated immunity.  
 
1.1.1 The Clonal Selection Hypothesis 
The number of naïve lymphocytes specific for any antigen is very small and the quantity of 
available foreign antigen may also be very small. As a result, distinct mechanisms are 
required to capture microbes, concentrate them and deliver their antigens to specific 
lymphocytes. Dendritic cells, located in epithelia and connective tissues, are the antigen 
presenting cells (APCs) of the adaptive immune system. They capture antigens, digest their 
proteins and display these peptides on their surface bound to 
major histocompatibility complex (MHC) molecules. Dendritic cells carry their antigenic 
cargo to draining lymph nodes and take up residence in the same region of the nodes through 
which naïve CD4
+ 
and CD8
+ 
T lymphocytes continuously recirculate. Specialised APCs 
display antigen to B lymphocytes and intact microbes or microbial antigens that enter lymph 
nodes or spleen are recognized in unprocessed (native) form by specific B lymphocytes. 
Antigen recognition provides specificity to the immune response, and the need for co-
stimulation ensures that T cells respond to microbes (the inducers of costimulatory molecules) 
and not to harmless substances. 
 
Antigen-specific clones of lymphocytes develop before and independent of exposure to 
antigen. When an antigen enters the body, it selects a pre-existing clone of lymphocytes and 
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activates it (Figure 1.1-2). This fundamental concept is called the Clonal Selection 
Hypothesis and was first described by Niels Jerne in 1955, and then more clearly enunciated 
by Macfarlane Burnett in 1957 
1
, as a hypothesis that could explain how the immune system 
can respond to a large number and variety of antigens.  
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Figure 1.1-2: The Clonal Selection Hypothesis.  
Each antigen (X or Y) selects a pre-existing clone of specific lymphocytes and stimulates the 
proliferation and differentiation of that clone. The diagram shows only B lymphocytes giving 
rise to antibody-secreting effector cells, but the same principle applies to T lymphocytes.  
[Taken from: Cellular and Molecular Immunology, 6
th
 edition. Abbas, Lichtman and Pillai. 
2007. Philadelphia: Saunders Elsevier, p. 15.]  
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1.1.2 The Immunological Synapse 
In the case of T cells, the adaptive immune response is initiated by the interaction of T cell 
antigen receptors (TCR) with MHC-peptide complexes in the nanometer scale gap between a 
T cell and an APC, referred to as the immunological synapse (IS) (Figure 1.1-3). The IS 
embodies a concept for understanding the high-order temporal and spatial cooperation of 
multiple biochemical and genetic elements known to be required for T cell activation.  
 
The mature IS has been defined by the bull’s eye arrangement of supramolecular activation 
clusters (SMACs) that form within a few minutes of T cell-APC contact (Figure 1.1-3b). The 
centre of the bull’s eye or cSMAC is enriched for TCR and MHC-peptide complexes. It 
includes the signalling molecules on the T cell cytoplasmic side of the IS, including protein 
kinase C θ (PKCθ). The ring of the bull’s eye or pSMAC contains the integrin Lymphocyte 
function-associated antigen 1 (LFA-1) and its major counter-receptor Intercellular adhesion 
molecule 1 (ICAM-1). Physiological T cell activation can be divided into a series of temporal 
stages: T cell polarization, initial adhesion, IS formation (initial signalling), and IS maturation 
(sustained signalling) 
2. Recruitment of PKCθ appears to be a marker for attainment of the 
stable IS 
3
 and maintenance of the stabilised IS for greater than 1 hour is well correlated with 
full T cell activation.  
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Figure 1.1-3: The Immunological Synapse 
4
. 
a) A profile view showing a selection of the key ligand pairs and signalling molecules that are 
involved in T-cell recognition. The stimulatory peptide–MHC molecule is shown in red, 
activating/co-stimulatory molecules are blue, inhibitory molecules are yellow and molecules 
that are not contributing to signalling are grey. The arrow indicates converging signals that 
lead to T-cell activation. b)The face on view of the synapse with the characteristic 'bulls-eye' 
zone pattern, including the central region of the supra-molecular activation complex 
(cSMAC) (yellow), the peripheral ring surrounding the cSMAC (pSMAC, green) and the 
region distal to the synapse outside the pSMAC (dSMAC, grey) as well the molecules/ligand 
pairs that are found enriched within. APC, antigen-presenting cell; CTLA4, cytotoxic T 
lymphocyte antigen 4; ICAM1, intercellular adhesion molecule 1; LFA1, leukocyte function-
associated antigen 1; PI3K, phosphatidylinositol 3-kinase; SHP2, SRC homology 2-domain-
containing protein tyrosine phosphatase 2; TCR, T-cell receptor; ZAP70, ζ-chain-associated 
protein 70. 
*
CD45 enters the cSMAC at later stages.  
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1.1.3 T lymphocyte Tolerance 
As I have very briefly discussed, the immune system uses many potent effector mechanisms 
to clear a broad range of both toxic and allergenic substances. Therefore it is critical that the 
immune response is able to avoid unleashing these destructive mechanisms against the 
mammalian host’s own tissues. The ability of the immune response to avoid damaging self-
tissues is referred to as self-tolerance. Failure of self-tolerance underlies the broad class of 
autoimmune diseases - a process that has been extensively studied. We now know that 
antigens may be administered in ways that induce tolerance rather than immunity, and this 
may be exploited for the prevention and treatment of autoimmune, as well as allergic, disease 
and transplant rejection.  
 
Immunological tolerance is unresponsiveness to an antigen induced by the exposure of 
specific lymphocytes to that antigen, and tolerance to self-antigens is a fundamental property 
of the adaptive immune system. Self-tolerance may be induced in immature self-reactive 
lymphocytes in generative lymphoid organs (central tolerance), or in mature lymphocytes in 
peripheral sites (peripheral tolerance). In the late 1980s, the advent of TCR transgenic systems 
and sensitive flow cytometric technology paved the way for several landmark studies that, by 
visualising the deletion of autoreactive thymocytes 
5, 6
, confirmed one of the central 
predictions of Burnet’s clonal selection theory 1. This ‘recessive’ mode of tolerance, also 
known as negative selection, has become a well-accepted paradigm, and more recent findings 
such as the discovery of ‘promiscuous gene expression’ 7 and the autoimmune regulator 
(Aire) 
8-10
 gene have been interpreted by many to indicate that central tolerance through 
negative selection is indeed essential to prevent spontaneous autoimmunity. However, as not 
foreseen by the clonal selection theory, it later turned out that intrathymic encounter of ‘self’ 
by developing T cells does not inevitably lead to their elimination from the repertoire. Instead, 
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recognition of cognate antigen by particular transgenic TCRs in the thymus was frequently 
found to increase the proportion and absolute number of natural T regulatory (nTreg) cells 
among thymocytes of the respective specificity (dominant tolerance) 
11
. Figure 1.1-4 provides 
an overall schematic for T-cell development in the thymus. The role of the avidity of antigen 
recognition in Treg differentiation versus clonal deletion has been most thoroughly addressed 
in the TCR-hemagglutinin (TCR-HA) transgenic system 
11
. A clear correlation was found 
between antigen expression levels and the resulting absolute number of specific nTregs, 
whereby ‘low’ expression levels favoured the generations of nTregs, whereas ‘high’ antigen 
doses favoured clonal deletion 
12, 13
. The best defined example of autoimmunity resulting from 
a defect in negative selection in the thymus is the autoimmune polyendocrine syndrome 
(APS). This group of diseases is caused by mutations in the Aire gene, and is characterised by 
antibody-and lymphocyte-mediated injury to multiple endocrine organs, including the 
parathyroids, adrenals and pancreatic islets. A mouse model of APS has been developed by 
knocking out the Aire gene. In normal mice, protein antigens thought to be restricted to these 
endocrine organs are expressed in thymic epithelial cells, and immature T cells specific for 
these antigens are deleted in the thymus. In Aire-knockout (KO) mice, these antigens are not 
displayed in the thymus and so T cells specific for these self-antigens escape deletion, mature 
and enter the periphery where they attack the target tissues.  
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Figure 1.1-4: Overall scheme of T-cell development in the thymus 
14
. 
Committed lymphoid progenitors arise in the bone marrow and migrate to the thymus. Early 
committed T cells lack expression of T-cell receptor (TCR), CD4 and CD8, and are termed 
double-negative (DN; no CD4 or CD8) thymocytes. DN thymocytes can be further subdivided 
into four stages of differentiation (DN1, CD44
+
CD25
-
; DN2, CD44
+
CD25
+
; DN3, CD44
-
CD25
+
; and DN4, CD44
-
CD25
-
). As cells progress through the DN2 to DN4 stages, they 
express the pre-TCR, which is composed of the non-rearranging pre-T  chain and a 
rearranged TCRβ-chain. Successful pre-TCR expression leads to substantial cell proliferation 
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during the DN4 to double positive (DP) transition and replacement of the pre-TCR -chain 
with a newly rearranged TCRα-chain, which yields a complete αβTCR. The αβ-
TCR
+
CD4
+
CD8
+
 (DP) thymocytes then interact with cortical epithelial cells that express a 
high density of MHC class I and class II molecules associated with self-peptides. The fate of 
the DP thymocytes depends on signalling that is mediated by interaction of the TCR with 
these self-peptide–MHC ligands. Too little signalling results in delayed apoptosis (death by 
neglect). Too much signalling can promote acute apoptosis (negative selection); this is most 
common in the medulla on encounter with strongly activating self-ligands on haematopoietic 
cells, particularly dendritic cells. The appropriate, intermediate level of TCR signalling 
initiates effective maturation (positive selection). Thymocytes that express TCRs that bind 
self-peptide–MHC-class-I complexes become CD8+ T cells, whereas those that express TCRs 
that bind self-peptide–MHC-class-II ligands become CD4+ T cells; these cells are then ready 
for export from the medulla to peripheral lymphoid sites. SP, single positive.   
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However, even with effective negative selection and dominant tolerance mechanisms, central 
tolerance is incomplete. In order to ensure that a wide repertoire of T cells is available in the 
periphery to combat foreign antigens, the threshold of clonal deletion is set low enough that T 
cells with TCRs expressing sub-threshold affinity for self-antigens mature and migrate to the 
periphery. In addition, T cells which recognise self-antigen derived peptides not expressed or 
presented in the thymus will also fail to be deleted. Control of these self-reactive T cells is the 
role of peripheral tolerance.  
 
Peripheral tolerance can act at several levels. The simplest scenario involves T-cell ignorance 
of self-antigens (Figure 1.1-5), either because the latter are sequestered in sites not easily 
accessible to the blood/lymph-borne immune system 
15, 16
, or because the amount of antigen 
does not reach the threshold required to trigger a T-cell response 
17
. Alternatively, T-cell 
encounters with self-antigen might lead to functional inactivation: anergy (Figure 1.1-5). 
Anergy was first shown in vitro as a result of TCR ligation in the absence of co-stimulation 
18
. 
However, later work implicated signalling through alternative receptors, rather than just lack 
of co-stimulation, in the induction of anergy 
19
. Even when T cells become fully activated, 
effective tolerance might still be maintained if the nature of the response is such that 
pathogenic effects are avoided (Figure 1.1-5). Just as certain cytokines and chemokines 
promote pathogenicity, regulating where self-reactive T cells go and what they make 
represents another mechanism to prevent autoimmune destruction in the periphery. 
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Figure 1.1-5: T-cell intrinsic mechanisms of peripheral tolerance.  
Self-reactive T cells might never encounter the self-protein they recognise and therefore exist 
in a state of ignorance. b) Encounter with self-protein might induce T-cell anergy, possibly 
involving interaction of the T-cell molecules CTLA-4 or PD-1 with their ligands (CD80/86, 
PDL1/2). c) T cells interacting with self-protein might undergo full activation, but might 
develop a non-pathogenic phenotype in terms of which cytokines and chemokine receptors 
they express. d) Self-reactive T cells might be deleted following contact with self-protein by 
activation-induced cell death involving upregulation of T-cell Fas ligand and subsequent 
signalling through the death receptor Fas. APC, antigen presenting cell; CTLA-4, cytotoxic 
T-lymphocyte-associated antigen 4; FasL, Fas ligand; MHC, major histocompatibility 
complex; PD-1, programmed cell death 1; PDL, PD-1 ligand; TCR, T cell receptor; TH cell, T 
helper cell. [Taken from: Walker LS & Abbas AK. Nat Rev Immunol 2002; p.13.]   
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However, arguably the most effective way to prevent autoimmune destruction by a given T-
cell clone is to delete that specificity from the repertoire by activation-induced cell death 
(AICD) (Figure 1.1-5) 
19
. As self-antigens cannot be easily cleared, repetitive TCR 
engagement might be a feature of T-cell encounters with self-proteins, which perhaps serves 
as a trigger for AICD 
19
. A key mechanism underlying AICD in CD4
+
 T cells, as well as B 
cells, is the ligation of the Fas death receptor by its ligand. Interest in this pathway came from 
the observation that the lymphoproliferative lupus-like syndrome in MRL/lpr and gld mice 
was associated with naturally occurring defects in Fas (CD95) and Fas ligand respectively 
20-
22
. The physiological importance of Fas signalling was underscored by the finding that defects 
in the Fas pathway in humans are associated with the autoimmune lymphoproliferative 
syndrome (ALPS) 
23
. However, it should be noted that peripheral deletion is rarely complete, 
and in many models the remaining cells are anergic, which indicates that removal of a T-cell 
clone from the peripheral repertoire is perhaps an over-representation of events. Instead, 
deletion might simply serve to decrease the precursor frequency to a level at which anergy can 
be effectively induced. 
 
Finally, a significant development in the field of tolerance has been the re-emergence of the 
concept that T-cell reactivity might be controlled extrinsically by a distinct subset of T cells 
with a regulatory function, and the development of these cells is the subject of my thesis.    
  
  
 
33 
1.2 T regulatory cells  
Treg cells are a subpopulation of T lymphocytes which modulate the immune system and 
maintain immune homeostasis. They uphold tolerance to self-antigens, moderate 
inflammation induced by pathogens and environmental insults, and abrogate autoimmune 
disease 
24-26
.  In addition, they can maintain allogeneic transplant tolerance in experimental 
models 
27
, but they also facilitate tumour escape from immune monitoring 
28
. Given this 
fundamental importance for immune function and their great potential for therapeutic 
modulation, it is no surprise that Tregs have attracted extraordinary interest. Despite this, our 
understanding of their development remains incomplete. 
 
More genome-wide transcriptional profiles have been generated on Treg cells than any other 
immune cell type 
29, which has resulted in the definition of a canonical “Treg signature” that 
distinguishes Treg cells from conventional T effector (Tconv) cells, at least in their resting 
states in lymphoid organs 
30-35
 (Table 1.2-1). The Treg signature includes genes over-
expressed or repressed in Tregs (in a proportion of 2 to 1), and genes that encode proteins 
with a wide range of cellular locations and functions: cell surface receptors, signalling kinases 
and transcription factors 
29
. Up to 1500 genes have been found to be differentially expressed 
in Treg cells 
35
, but none or very few of these differences are absolute; instead, these 
variations correspond to quantitative differences between Tregs and Tconv cells 
29
. Nor are 
they specific, as almost all transcripts overexpressed in Treg cells can also be found in non-T 
cell lineages 
29
. Thus, for simplicity, Tregs are generally defined by their expression of the 
intracellular transcription factor, Forkhead box P3 (FOXP3), in addition to surface phenotypic 
markers CD4 and CD25 
36
.   
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Gene product 
cellular 
localization 
Gene 
name 
Gene product putative function Over-/under-
expressed in resting 
Tregs 
    
Membrane Igfbp4 Protein binding Under-expressed 
 Sh3bgrl2 Receptor Over-expressed 
 Prnp Receptor Over-expressed 
 Itgae1 Receptor Over-expressed 
 Kirg1 Receptor Over-expressed 
 Ctla4 Receptor Over-expressed 
 Rgs1 Receptor Over-expressed 
 Slc22a2 Receptor Over-expressed 
 Tnfrsf4 Receptor Over-expressed 
 Tnfrsf9 Receptor Over-expressed 
 Il2rb Receptor Over-expressed 
 Il2ra Receptor Over-expressed 
 Nrp1 Receptor Over-expressed 
 Gpr83 Receptor Over-expressed 
 Nt5e Receptor Over-expressed 
 Itgb3 Receptor Under-expressed 
 Vipr1 Receptor Under-expressed 
 Klrd1 Receptor Under-expressed 
 Il1rl2 Receptor Under-expressed 
 Rgmb Receptor Under-expressed 
 App Receptor Under-expressed 
 Ptger2 Receptor Under-expressed 
 Tgfbr3 Receptor Under-expressed 
 Sema4f Receptor Under-expressed 
    
Cytoplasm Rgs16 GTP or ATP binding Over-expressed 
 Socs2 GTP or ATP binding Over-expressed 
 Tiam1 Receptor Over-expressed 
 Map3k8 Kinase or phosphatase Over-expressed 
 Sgk1 Kinase or phosphatase Under-expressed 
 Appl2 GTP or ATP binding Under-expressed 
 Rapgef4 GTP or ATP binding Under-expressed 
 Myo10 GTP or ATP binding Under-expressed 
 Arhgap29 GTP or ATP binding Under-expressed 
 Sgms1 Transferase or esterase Under-expressed 
 Hs3st3b1 Transferase or esterase Under-expressed 
 St3gal6 Transferase or esterase Under-expressed 
 Pde3b Transferase or esterase Under-expressed 
    
Nucleus Plagl1 DNA binding or transcription factor Over-expressed 
 Mdfic DNA binding or transcription factor Over-expressed 
 Ikzf4 DNA binding or transcription factor Over-expressed 
 Ikzf2 DNA binding or transcription factor Over-expressed 
 Irf4 DNA binding or transcription factor Over-expressed 
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 Foxp3 DNA binding or transcription factor Over-expressed 
 Dusp4 Kinase or phosphatase Over-expressed 
 Enc1 Protein binding Under-expressed 
 Pole2 DNA binding or transcription factor Under-expressed 
 
Table 1.2-1: Treg cell signature genes and their cellular localization 
29
.  
A list of the most differentially expressed genes from a consensus Treg signature 
35
, either 
over-expressed or under-expressed in resting Treg cells of spleen or lymph node relative to 
Tconv cells. Gene products are grouped according to their cellular localization and their 
putative functions identified.   
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The majority of Tregs develop naturally in the thymus (nTregs) as a subpopulation of CD4
+ 
T 
cells. They are positively selected and migrate to the periphery. As I have already alluded to, 
it is thought that self-peptide - MHC recognition by the TCR is required with an avidity 
intermediate between that necessary for positive selection of conventional CD4
+
 and CD8
+
 T 
(Tconv) cells and that needed for the deletion of autoreactive T cells 37. In addition to these 
naturally-occurring nTregs, transforming growth factor beta (TGF-β) and interleukin- (IL-) 2 
are able to promote, in response to TCR/CD28 co-stimulation, the differentiation of peripheral 
naive CD4
+ 
T cells into CD4
+
CD25
+
FOXP3
+ 
T cells, otherwise known as inducible (i) Treg 
cells, that possess T cell suppressive properties akin to those of nTregs 
38-40
. nTregs are 
thought to suppress autoimmunity while iTregs restrain immune responses to foreign 
antigens, such as those from diet, commensal bacteria and allergens 
41
.  
 
The importance of Treg cells is underscored by the lymphoproliferative and multi-organ 
autoimmunity phenotypes of Scurfy mutant mice (Figure 1.2-1) and the human conditions 
Immunodysregulation Polyendocrinopathy and Enteropathy, X-linked (IPEX) syndrome and 
X-Linked Autoimmunity-Allergic Dysregulation syndrome (XLAAD), which result from 
mutations in the Foxp3 gene and consequent lack of Tregs 
42
.  
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Figure 1.2-1: T regulatory cells maintain tolerance to self 
Scurfy mutant mice (right) with a genetic FOXP3 (also known as scurfin) deficiency, and 
consequent lack of Treg cells, develop multi-organ autoimmune disease and die soon after 
birth. Observable phenotypes include cachexia and runting, flaking, crusty skin on eyelids, 
ears and tail, dermal thickening and squinted eyes. An age-matched, healthy, wild-type 
control mouse (left) is shown for comparison.    
 
 
  
Wild-type 
Scurfy 
mutant 
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1.3 T regulatory cells in health 
Pregnancy represents a physiological situation where tolerance to paternal alloantigens, 
(antigens from a genetically disparate individual of the same species) is critical for successful 
reproduction of placental animals and Tregs are thought to facilitate this, based on their 
increased numbers in pregnant mice and humans 
43
. Samstein et al recently demonstrated that 
pregnancy-induced maternal iTregs specifically recognise paternal antigens, indicating that 
maternal-fetal tolerance to paternal alloantigens is an active process in which iTregs 
specifically respond to paternal antigens to induce tolerance 
44
. These findings are consistent 
with an increase in the percentage of Tregs during pregnancy and with no such increase in 
women suffering recurrent pregnancy loss 
43
. The authors go on to speculate that these results 
may provide biological plausibility for the seemingly paradoxical observation that, among 
women with a history of unexplained recurrent miscarriage, the administration of Filgrastim 
(granulocyte colony-stimulating factor) in early miscarriage reduces the rate of miscarriage 
45
.    
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1.4 T regulatory cells in disease 
While Tregs are indispensable for the maintenance of self-tolerance and immune homeostasis, 
their dysfunction can cause fatal autoimmune disease, immunopathology and allergy.  
 
1.4.1 T regulatory cells in autoimmune disease 
To address the question of whether immune suppression by Treg cells is impaired in the 
setting of human autoimmune disease, it is important to recognise the potential means by 
which such a defect may occur. Defects in the number and function of Tregs, as well as the 
resistance of  Tconv cells to Treg cell-mediated suppression, could each contribute to failed T 
cell regulation 
46
. The number of Treg cells found in individuals with autoimmune disease is 
itself influenced by Treg cell development, persistence and proliferation in the periphery, and 
homing to the site of inflammation 
46
. Each of these defects in regulation may contribute, 
either in isolation or in combination, to the development of human autoimmune disease.  
 
Treg dysfunction in autoimmune disease may be due to a defect in one of the many 
mechanisms through which Treg cells function 
47
. This could occur through inadequate 
expression of cell surface molecules that are known to be involved in contact-dependent 
suppression (such as, cytotoxic T lymphocyte antigen 4 (CTLA4), CD39, lymphocyte 
activation gene 3 (LAG3), granzyme A and CD95 (also known as FAS)), or as a result of a 
failure to produce the soluble factors (such as TGFβ, IL-10 and IL-35) that are involved in 
some aspects of suppression 
46
. Underlying genetic factors may influence these mechanisms. 
In addition, the composition of the local milieu, including the types of antigen-presenting 
cells and cytokines such as tumour necrosis factor (TNF) 
48
, IL-4 
49
, IL-6 
50
, IL-12 
51
, IL-15 
52
 
and IL-21 
53
, can influence Treg cell function.  
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Multiple mechanisms by which Tconv cells resist Tregs have been proposed 
54
. Cell-intrinsic 
resistance to suppression has been shown to occur in CD4
+
 memory T cells and T helper 17 
(Th17) cells 
55
. The cytokines IL-2, IL-4, IL-7 and IL-15 support the proliferation of Tconv 
cells in the presence of Tregs, indicating that despite the favourable roles of these cytokines in 
Treg homeostasis 
56
, the presence of these cytokines in the short term allows Tconv cells to 
bypass suppression by Tregs 
46
. In addition, several members of the TNF receptor family have 
been implicated in this process: antibody specific for CD134 (also known as OX40 or Tumour 
Necrosis Factor Receptor Superfamily Member (TNFRSF) 4 ) abrogates suppression when 
bound to Tconv cells 
57
 and ligation of CD137 (also known as 4-1BB or TNFRSF9) results in 
suppression-resistant T conv cells 
58
.     
 
The task of determining the extent and character of these defects in human disease is therefore 
challenging. Evidence that an inadequate number of Tregs leads to autoimmunity in humans 
is most clearly shown in patients with IPEX, who completely lack Tregs as a result of a 
mutation in the foxp3 gene 
42
, but most patients with autoimmune disease probably have a 
more modest reduction in Tregs. The task of enumerating Tregs in human disease is 
complicated by a number of issues. The lack of a cell surface marker unique to Tregs and the 
multiplicity of Treg subsets lead to the issue of which cells to count.  
 
With the discovery that expression of FOXP3 has a central role in the differentiation and 
maintenance of Tregs 
59, 60
, the use of flow cytometry-based analysis of FOXP3 expression in 
T cells became the gold standard for defining Tregs. But, FOXP3 is a nuclear protein and so 
assessment of its expression in T cells requires fixation and permeabilisation of the cells, 
resulting in an inability to obtain viable cells for further functional analysis 
46
.  Furthermore, 
does the peripheral blood reflect the global number of Treg cells in the body and, more 
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specifically, their number in inflamed tissues? Patients are often on medications which limit 
their disease but are also likely to interfere with the Treg population and its functions.  These 
reasons alone emphasise the complexities of this subject and limit the conclusions that can be 
drawn from individual studies.  
 
Identifying defects in the function of Tregs is made difficult both by the multiple mechanisms 
they use to suppress inflammation 
61
 and by the manner in which suppression is measured. 
Assessment of Treg function in humans requires the use of in vitro assays that, owing to the 
rarity of Tregs in the peripheral blood (5-10% of the total peripheral CD4
+ 
T cell population in 
humans, under basal conditions 
24
), must be carried out with low cell numbers limiting the 
type and quality of assays that can be done. In vitro assays provide insight into potential Treg 
defects but they cannot account for the impact of the local milieu on Treg function 
46
.  
 
The resistance of Tconv cells to Tregs has been observed in several animal models of 
autoimmunity. In these models, inflammation and tissue destruction progress despite the 
presence of functional Tregs at the site of inflammation 
46
. Such findings suggest that a 
resistance of Tconv cells to Tregs may contribute to disease progression and this phenomenon 
has been described in two mouse models of diabetes: non-obese diabetic mice (NOD) mice 
62, 
63
 and DO11.10 RIP-mOVA mice 
53
; experimental autoimmune encephalomyelitis (EAE) 
64
and the MRL-lpr model of systemic lupus erythematosus (SLE) 
65
.  
 
For the reasons described here, delineation of the mechanisms of impaired tolerance in human 
autoimmune disease has been challenging and slow. Nevertheless, a picture is slowly 
emerging and with it, a hope is that this knowledge can direct the development of new 
approaches to the treatment of autoimmunity. A comprehensive review of what is known 
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about the role of Tregs in individual autoimmune diseases is beyond the scope of this work 
but I briefly discuss the evidence supporting the involvement of impaired T cell regulation in 
the context of five of the more common autoimmune and inflammatory diseases below. 
 
1.4.1.1 T regulatory cells and type-1 diabetes 
Type-1 diabetes is an immune-mediated disease that results in inflammation and destruction 
of the pancreatic islet cells, resulting in a lifelong need for insulin. The current evidence does 
not indicate a global deficiency in Treg numbers in type-1 diabetes 
66, 67
 but does not rule out 
a more focal deficiency in the Treg compartment, with respect to either a subset of Tregs 
67
 or 
the specificity of Tregs for islet antigens 
68
. Multiple studies show that suppression is 
impaired 
69
 and indicate that this is, in part, due to the resistance of Tconv cells to suppression 
by Tregs 
70, 71
.  
 
1.4.1.2 T regulatory cells and multiple sclerosis 
Multiple sclerosis (MS) is an autoimmune disease characterised by inflammatory lesions and 
degeneration in the central nervous system (CNS). The pathogenic CD4
+
 T cells in MS target 
myelin-based antigens 
46
. They have the ability to migrate to the CNS as well as unique 
effector functions 
72
. Although the inflammatory components involved in MS are numerous, 
defects in Tregs are implicated by both the mouse model of MS, experimental autoimmune 
encephalomyelitis (EAE) and the human disease. Overall, Tregs do not seem to be reduced in 
number but clear defects in suppression have been identified 
73, 74
.  
 
 
1.4.1.3 T regulatory cells and systemic lupus erythematosus 
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Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by the 
presence of autoantibodies and immune complexes that target multiple organ systems, 
including the skin, joints, kidneys and CNS. Unlike the autoimmune diseases discussed 
above, there are many target tissues in SLE, not just one, and it is thought to be a largely B 
cell-mediated disease 
46
. Defects in the number 
75-78
 and function of Tregs 
75, 79, 80
 and in the 
resistance of effector T conv cells to suppression 
75, 81
 have been established. The observations 
of numerous possible regulatory defects may reflect the systemic nature of this disease or a 
more significant role for Tregs in SLE, compared with their role in other autoimmune 
conditions 
46
.  
 
1.4.1.4 T regulatory cells and rheumatoid arthritis 
As in other autoimmune diseases, the experimental model of rheumatoid arthritis (collagen-
induced arthritis) is exacerbated by the depletion of Tregs 
82
. But, unlike the majority of 
diseases described above, the target tissue – synovium – can be obtained from patients with 
rheumatoid arthritis which has allowed investigators to analyse the number and function of 
Tregs in the diseased tissue, as well as the peripheral blood. (Analysis of cerebrospinal fluid 
offers a similar advantage to the study of MS.) In addition, studies of rheumatoid arthritis 
benefit from the existence of well-established biological therapies, allowing the impact of 
these therapies on Treg numbers and function to be studied e.g. the TNF-specific agent 
infliximab (Remicade®, Merck) 
46
. There is a general agreement that the percentage of Tregs 
is higher in the synovial fluid of patients with rheumatoid arthritis compared to controls 
83-85
. 
Ehrenstein et al 
86
 established a Treg cell-intrinsic defect in interferon gamma (IFN-γ) and 
TNF production, as well as a defect in CTLA4-mediated inhibition of TCR signalling in 
patients with rheumatoid arthritis. Resistance of Tconv cells to suppression has not be 
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exhaustively tested in rheumatoid arthritis and was not the reason for the impaired 
suppression observed by Ehrenstein et al 
86
.  
 
1.4.1.5 T regulatory cells and inflammatory bowel disease  
The term inflammatory bowel disease (IBD) refers to two conditions - Crohn’s disease and 
ulcerative colitis – distinguished by their underlying pathology. Despite these pathological 
differences, both are thought to be Tconv cell-driven diseases and to result from a loss of 
immune tolerance in the gut 
46
. Tregs have a central role to play in the maintenance of 
immune tolerance in the gut, which is exemplified by the wasting disease and gastritis that 
develop in Scurfy mice lacking Treg cells, and by reversal of the disease by adoptive transfer 
of Tregs 
87
. A role for Tregs in human disease is supported by the finding of severe bowel 
inflammation in IPEX patients 
42
. Like rheumatoid arthritis, studies of Tregs in IBD have 
been aided by the ability to study their role in target organs as well as peripheral blood, but 
these studies have given mixed and often contradictory results with no clear picture 
explaining the role of Tregs in IBD currently 
88-93
.  
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1.4.2 T regulatory cells and cancer  
Under normal circumstances, where Tconv cells accumulate in response to local signals, so do 
nTregs. The homeostatic balance is maintained and potential tissue damage prevented 
94
.  In 
the environment of solid tumours, however, a conversion of Tconv cells into iTregs occurs, 
creating a poll of highly activated and indiscriminately suppressive iTregs, which interfere 
with functions of anti-tumour Tconv cells 
95, 96
. nTregs control cancer-associated 
inflammation which is thought to favour tumour progression but it is iTregs that are thought 
to play the more major role in cancer and cancer therapy 
94
. For this reason, it is widely 
believed that in vivo elimination of iTregs may restore or enhance anti-tumour immunity and 
increase the efficacy of immunotherapy 
94
.   
 
The division in labour between iTregs and nTregs is not absolute but it is reasonable to 
assume, albeit simplistically, that Tregs circulating in the peripheral blood of healthy donors 
largely represent thymus-derived nTregs responsible for maintaining peripheral tolerance, 
whilst those present in cancer patients are enriched with iTregs, and this allows for a 
discrimination between Treg subsets in health and disease. Having said that, aggregate results 
of recent clinical trials using Treg-depleting regimens, such as anti-CD25 dacluzimab and 
denileukin diftitox (ONTAK®) in cancer patients suggest that the indiscriminate elimination 
of CD25
+
 T cells interferes with anti-tumour functions of Tconv cells as well as Tregs 
94
, and 
so more specific iTreg therapeutic targets are required. The selective discrimination between 
nTreg and iTreg to avoid shifting the balance toward autoimmunity and simultaneously 
achieve robust anti-tumour effects will not be simple and additional knowledge of the 
molecular mechanisms underlying iTreg and nTreg interactions is required. 
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1.4.3 T regulatory cell therapy and transplantation* 
Transplantation can be defined as the artificial transfer of cells, tissues or organs from one 
individual to another. Where the graft is syngeneic (genetically identical to the host, e.g. 
transplantation between identical twins) or autologous (a transplant from one individual to 
itself, e.g. using stored blood for autotransfusion), there is perfect histocompatibility and no 
significant immune response is elicited 
97
. In this situation, the recipient is fully tolerant to the 
transplant and accepts it without a rejection phenomenon. Where there is histoincompatibility, 
however, in general an immune response is elicited against the foreign antigens, the 
magnitude of which determines acceptance or rejection of the transplanted tissues 
97
.  
 
Since the first human kidney transplant carried out by Dr Joseph Murray in 1954 between 
identical twins, the regular development of new chemical immunosuppressants, as well as 
improved surgical and ancillary care, have led to dramatic increases in kidney allograft 
survival rates and enabled the transplantation of livers, hearts, pancreases and lungs, as well 
as composite tissues 
98
. Nonetheless, substantial problems remain and improvements in short-
term (1 year) allograft survival have not been paralleled by gains in long-term graft survival 
(US organ procurement and Transplantation network. Annual Data report 2011. Accessed 
17
th
 July 2013). The reasons for graft loss are complex but can, at the risk of 
oversimplification, be broadly classified into three categories: inflammation-induced reactions 
against graft tissues, immune–initiated reactions against graft tissues and direct organ toxicity 
by the immunosuppressive drug.  Other side effects of immunosuppression, such as 
susceptibility to opportunistic infections, malignancy and accelerated cardiovascular disease, 
contribute substantially to morbidity and mortality amongst transplant recipients. Thus it 
stands to reason that the ability to induce transplantation tolerance – good allograft function in 
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the sustained absence of immunosuppressive therapy – could be expected to have an 
enormous impact on both allograft and patient survival, and that it is a goal worth pursuing.  
 
In recipients of solid-organ transplants, the high frequency of alloantigen-reactive Tconv cells 
in the immune repertoire of the recipient compared with the relatively small number of Treg 
cells present at the time of transplantation means that the balance of cells is shifted towards 
allograft destruction 
55
. This crucial balance between graft destruction and regulation can be 
shifted using strategies to inhibit the activity of Tconv cells and/or increase the relative 
frequency or functional activity of alloantigen-reactive Treg cells 
99-103
. Previous experimental 
studies using MHC-mismatched combinations in murine skin and heart allo-transplantation 
have shown that alloantigen-specific Tregs are more effective at inducing indefinite allograft 
survival than polyclonal Tregs 
104-106
. In 2011, Sagoo et al translated these observations into a 
human in vivo model 
107
. Human Tregs were enriched from peripheral blood donations from 
healthy volunteers and stimulated with irradiated mature myeloid dendritic cells (DCs). The 
Tregs were then sorted and expanded if they expressed two activation markers, CD69 and 
CD71, after allospecific activation with the DCs in vitro. Transfer of these customised Tregs 
into a humanised mouse skin transplant model prevented transplant rejection and skin damage 
with higher efficacy than that associated with the transfer of nonspecific, polyclonal Tregs. 
No clinical trials of Treg therapy in solid organ transplantation have been undertaken as yet 
but promising data are emerging from early trials of Tregs for the prevention of graft-versus-
host disease (GVHD) post hematopoietic stem-cell transplantation 
108-110
 and the ONE Study - 
a multicentre Phase I/II study funded by the European Union Seventh Framework Programme 
– has set about investigating the safety of infusing ex vivo-expanded Treg cells into kidney 
transplant recipients (www.onestudy.org).  
*Please see: Salisbury E, Game D, Lechler R. Transplantation Tolerance. Pediatric Nephrology. (In Press) for a more detailed review. 
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1.5 Natural T regulatory cell development 
Since the description of suppressor T cells in the early 1970s, considerable progress has been 
made in the characterisation of Treg cells but the signalling events necessary for nTreg 
development in the thymus are not fully understood. Three main signals have been identified. 
Firstly, as I suggest earlier, it is thought that self-peptide – MHC  recognition by the TCR is 
required with an avidity intermediate between that necessary for positive selection of Tconv 
cells and that needed for the deletion of autoreactive T cells 
37
. Secondly, costimulatory 
signals play an important role. We know mice deficient in CD28, its ligands CD80 and CD86, 
or CD40, or LFA1 all display a marked reduction in nTregs 
25, 111-113
. Thirdly, IL-2, in 
combination with IL-15 or IL-7, is also known to be crucial for nTreg development 
36
. 
Whereas single absence of IL-2 or CD25 (the IL-2Rα-chain) mildly impacts thymic nTreg 
development 
114-116
, mice lacking both IL-2 and IL-15, or CD122 (the IL-2βR chain common 
to both IL-2 and IL-15 receptors), or CD132 (the common γ-chain), or Signal Transducer and 
Activator of Transcription 5 (STAT5α/β) (the transcription factor downstream of IL-2R) are 
all devoid of nTregs 
116-122
. Conversely, transient or transgenic expression of STAT5 can 
rescue nTreg numbers in mice deficient in IL-2, CD25, CD122 or CD132 
116, 118, 123, 124
, as 
well as, notably, CD28 
118
. STAT5 is known to have binding sites within the Foxp3 promoter 
116, 121
.  
 
Based on these and other data, a two-step model of nTreg development has been projected 
(Figure 1.5-1) in which an initial TCR/CD28-mediated signal is required for activation of the 
Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NFB) and c-Jun N-terminal 
kinase (JNK) pathways, and the consequent induction of common gamma chain (c) cytokine-
responsive FOXP3
-
 Treg precursor cells from immature thymocytes 
25
. Two precursor 
populations of nTreg cells have been described: CD4
+
CD8
+
 thymocytes that express FOXP3 
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30, 125
 and a more distal CD4
+
CD8
-
CD25
+
CD122
+
GITR
+
FOXP3
-
 thymocyte population 
126
.  
Whether the proximal precursor gives rise to the distal precursor prior to mature nTreg cell 
generation is not known, but in the second step of nTreg development these distal, now γc 
cytokine-responsive, FOXP3
-
 Treg precursor cells are exposed to IL-2 in the absence of new 
TCR/CD28 ligation, resulting in their differentiation into mature FOXP3
+
 nTreg cells 
118, 126
.   
 
Despite this, how the signals arising from multiple receptors are integrated to drive the events 
necessary for thymic nTreg development in vivo is far from resolved and much of what we do 
know is based on data extrapolated from co-transfection studies in T cell lines 
127, 128
.  
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Figure 1.5-1: The two-step model of nTreg cell development.  
A schematic diagram illustrating the putative two-step model of nTreg cell 
development from immature thymocytes. 
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1.6 This study 
Using an unbiased forward genetic approach, I set out to identify dominant genes required for 
the development of nTregs in the thymus with the aim of enhancing our knowledge in this 
fundamental area of immunobiology.  
 
1.6.1 Forward genetics and N-ethyl-N-nitrosourea (ENU) mutagenesis 
Genetics originally began with phenotype.  The aim was to find the genes responsible for 
phenotype. This era was interrupted by methods such as the “knock-in/knock-out technology” 
which permitted the identification of genes irrespective of what they did: “reverse genetics”.  
Reverse genetics requires a hypothesis driven guess on the nature of the molecules of interest 
and is limited by the lethal nature of complete disruption of genes that control proliferation, 
cell death or senescence 
129
.  This project returns to classical genetics. Enlightened by 
technologies of the modern era, it is now known as “forward genetics” 129. The strength of 
forward genetics lies in its unbiased approach and bringing a robust phenotype to the 
forefront.  
 
Forward genetics requires phenotypes and this is the task of mutagenesis.  Powerful germline 
mutagens exist to increase the rate of naturally-occurring mutations in mammals ~100-fold.  
The chemical mutagen N-ethyl-N-nitrosourea (ENU), an alkylating agent, offers an advantage 
over other compounds by operating at the level of spermatogonia, creating “stable” mutations 
that are transmitted in the germline for the lifetime of the animal after mutagenesis 
129
.  It 
creates chiefly A→G transitions and A→T transversions randomly throughout the genome 
129
.  ENU has the capacity to generate a range of alleles at any locus, and subtle hypomorphic 
variations can provide functional insights that binary all-or-nothing gene knockouts often 
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obscure.  Since the mutations are generated randomly, no assumptions are made regarding the 
nature of the disrupted gene, and the alleles are by definition viable in the adult. Figure 1.6-1 
explains the process of ENU mutagenesis.  
 
Analysis of mutation frequency by direct genomic sequencing is now available and the 
consensus of several groups would indicate that ENU induces a single base-pair change 
approximately every 0.5 to 1.0 megabase of genomic DNA 
130
. This frequency predicts that 
approximately 1,000 generation (G) 1 animals (or their progeny) need to be screened in order 
to identify a phenotype caused by a mutation in a single gene 
130
.  
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C57BL/6 +/+ male E-male C57BL/6 +/+ female
G1 +/- male
Screen for phenotype 
(Dominant)
C57BL/6 +/+ female
G2 +/+ or +/- femaleG1 +/- male 
G3 +/+ or +/- or -/- male
Screen for phenotype 
(Recessive)
ENU
 
 
 
Figure 1.6-1: N-ethyl-N-nitrosourea (ENU) mutagenesis  
C57BL/6 male mice are treated with 3 doses of ENU (referred to as “E-male” in diagram) 
and allowed to recover fertility over a period of 12 weeks. These males are then mated with 
wild-type (Wt) (+/+) C57BL/6 female animals and the resulting offspring from this cross are 
referred to as generation (G) 1 mice. They can be screened directly for dominant, 
heterozygous (+/-) traits or mated with Wt (+/+) animals to produce a G2 population. The 
G2 animals are heterozygous (+/-) or Wt (+/+) at any given locus. They can then be 
backcrossed to their G1 heterozygous (+/-) parents to generate G3 animals, some of which 
will be homozygous (-/-) at various (and random) locations throughout the genome. These G3 
animals can be screened for recessive mutations.   
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Treg cell development cannot be studied in vitro. A model organism with an adaptive immune 
system is required. Invertebrates have no true lymphoid organs. Zebrafish provide a vertebrate 
model but the mouse model is most closely related to humans. All but a few hundred of our 
approximately 25,000 expressed genes have direct mouse counterparts 
131
, and the mouse and 
human genomes demonstrate extensive synteny. These similarities could be applied to most 
mammals but use of the mouse model avoids more emotive species, whilst allowing the 
exploitation of powerful genetic techniques and molecular reagents. Mice are small, easy to 
maintain in the laboratory and have a short breeding cycle of approximately 8 weeks.  They 
can produce 8-10 offspring per litter and at least one litter per month. This makes them 
suitable for genetic analysis. In accordance with ethical principles and the requirements of the 
Secretary of State, reasonable efforts were made to incorporate replacement, reduction and 
refinement alternatives into the plan of this work.   
 
The random germline mutagenesis strategy has proved paramount to the discovery of 
previously uncharacterised genes and the identification of new functions of known genes or 
specific protein domains but, it is only ever as strong as its phenotypic screen. Successful 
screens need to be reliable (based on strong wild-type phenotypes to reduce the number of 
false negatives) and the standard deviations for each parameter must be as small as possible so 
“cut off values” can be defined and isolation of false positives minimised. In addition, the 
screen should be simple and rapid because it is performed on a large number of mice each 
week. The combination of mutations required to produce truly revolutionary phenotypic 
change will never be observed in a panel of ENU mutant mice.  True redundancy of function 
is unusual but overlap of function is exceedingly common and many phenotypic differences 
prove to be polygenic, limiting the effectiveness of phenotypic screens 
25
.  For this reason a 
great deal of ingenuity and screening is required to disclose function, and precisely the correct 
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molecule must be chosen to reveal the essential nature of a particular gene. One must consider 
whether the surrogate marker is truly indicative of the process
132
.  
 
Understanding whether a phenotype is heritable and, if so, whether it is dominant or recessive, 
is crucial to the design of subsequent mapping studies. As well as those mice which develop 
distinct phenotypes as a result of an inherited, spontaneous or ENU-induced mutation, there 
will always be a small, predictable fraction with phenotypes arising as a result of their 
position in the tail of a normal distribution curve for a quantitative trait. Others will have 
outlying phenotypes resulting from environmental factors in utero or post-partum. Setting up 
test crosses and examining the phenotype of the resulting progeny can distinguish between 
these possibilities. Once the isolated mutation is confirmed to affect the germline, a stable 
mutant stock is established.  
 
Genotyping and phenotyping are usually performed in parallel, until the identity of the 
affected gene is required for a more thorough in-depth phenotyping 
133
. Mutations are 
identified by a combination of mapping and sequencing. Mapping can be divided into two 
stages: a low-resolution phase in which the mutation is localised to a large chromosomal 
interval, and a high-resolution phase in which the size of the interval is reduced to a point at 
which sequencing can begin 
132
. Depending on the resources available, it might be necessary 
to prioritise the genes in the interval for sequencing. Properties that would influence this 
include whether mutations in the gene itself or in genes in the same biochemical pathway are 
known to yield a similar phenotype to the mutation under investigation, whether the gene is 
expressed in tissues that are known to be affected by the mutation, whether the level of 
expression and size of transcription differ in affected and unaffected mice; and whether there 
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is evidence for the existence of a bona fide transcript 
132
. Figure 1.6-2 summarises the 
practical steps required for germline mutagenesis. 
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Figure 1.6-2: The practical steps required for germline mutagenesis. 
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1.6.1.1 Past successes using forward genetics  
Early forward genetics projects led to the identification of the adenomatosis (APC) gene 
134
 
and the circadian locomotor output cycles kaput (clock) gene 
135
.  More recently, Beutler's 
group based at The Scripps Research Institute, La Jolla, USA has had outstanding success in 
identifying components of toll-like receptor signal transduction pathways, providing 
invaluable insights into the innate immune system 
136
.  In fact, together with Jules Hoffmann, 
Beutler received one-half of the 2011 Nobel Prize in Physiology/Medicine, for "their 
discoveries concerning the activation of innate immunity". (The other half went to Ralph 
Steinman for "his discovery of the dendritic cell and its role in adaptive immunity".)  
 
Of course, the ultimate aim of forward genetics is to link a change in phenotype with a 
defined change in genotype and harness this knowledge to find treatments for disease.  In 
2006, forward genetics led to the identification of ‘triple D’ (3d), a mis-sense allele of 
Unc93b1, which encodes the 12-membrane-spanning protein UNC-93B 
137
.  The mutation 
caused diminished MHC class II presentation of exogenous antigen and hyper-susceptibility 
to infection by mouse cytomegalovirus and other microbes.  Later that year, Casrouge et al  
went on to elucidate a genetic aetiology for herpes simplex virus-1 (HSV-1) encephalitis 
(HSE) in  two children with autosomal recessive deficiency in the intracellular protein UNC-
93B, resulting in impaired cellular interferon-α/β and –λ antiviral responses 138.  They 
demonstrated that HSE could result from a single-gene immunodeficiency that does not 
compromise immunity to most pathogens, unlike most known primary immunodeficiency 
syndromes, raising the possibility that other severe infectious diseases could reflect 
monogenic disorders of immunity.  These results have important therapeutic implications, as 
at least some HSE patients would benefit from recombinant IFN-α treatment.  Where reverse 
genetics may fail, forward genetics may succeed.   
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Chapter 2: Results 
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2.1 Dominant mutations Vulpo and Zerda impair nTreg development 
ENU-induced germline G1 mutants (n=766) were screened for dominant mutations that 
impair nTreg cell development. Abnormal nTreg cell development was defined as a 
CD25
+
FOXP3
+
CD4
+ 
cell population out with 2 standard deviations (SD) of the mean. Chronic 
antigenic exposure represents one of the main sources of iTregs 
139
 and therefore, it was 
expected that these non-immunised, 6-week old mice housed under clean, specific pathogen-
free conditions had a negligible iTreg contribution. Two ENU mutant mice, Vulpo and Zerda, 
with >90% reduction in the frequency of FOXP3
+
CD25
+
CD4
+ 
cells in peripheral blood 
leucocytes (PBL) by flow cytometry, compared to the mean value for the 766 animals 
screened (p<0.001), were identified (Figure 2.1-1). These dominant mutations were 
confirmed to be heritable in the germline. G2 phenodeviant mutants were inter-crossed and 
the G3 offspring screened and inter-crossed to establish homozygous strains.  
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Figure 2.1-1: Identification of Vulpo and Zerda mutants with impaired nTreg cell 
development.  
(A) A representative dot plot defining the percentage of FOXP3
+
CD25
+
 nTreg cells in the 
CD4
+ 
T lymphocyte population from PBL in one Wt mouse (top panel) and one heterozygous 
ENU mutant mouse (Mutant +/-) (bottom panel). Forward scatter plot allowed the exclusion 
of non-singlet cells and gates were applied to the lymphocyte and CD4
+
 populations in order 
to define the FOXP3
+
CD25
+
/CD4
+ 
population. (B) Two ENU mutant mice, Vulpo and Zerda, 
with reduced FOXP3
+
CD25
+
/CD4
+ 
Treg cell frequencies in PBL (values out with 2 SD of the 
mean). Each symbol represents data from an individual mouse. n=766. The graph is the 
cumulative result of at least 20 independent experiments. 
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The level of nTregs (CD25
+
Foxp3
+
/CD4
+
 cells) in the PBL of homozygous mutant Vulpo 
mice was only 12.8% of Wt (87.2% reduction) (p<0.0001) (Figure 2.1-2A). The level of 
nTregs in the PBL of homozygous mutant Zerda mice was only 3.4% of Wt (96.6% 
reduction) (p<0.0001) (Figure 2.1-2A). Organ dissection supported these findings (Figure 
2.1-3). I observed a 57.5% decrease in absolute number of nTregs in the thymus of Vulpo 
mutants (mean = 4.2 x 10
5
 +/-1SD (8.9 x 10
4
) cells, n=5) and a 92.2% decrease in absolute 
number of nTreg cells in the thymus of Zerda mutants (mean = 7.8 x 10
4 
+/-1SD (4.9 x 10
3
)
 
cells, n=6) compared to Wt (mean = 1 x 10
6
 +/-1SD (8.7 x 10
4
)
 
cells, n=6) (Figure 2.1-3). 
The absolute number of nTregs in the thymus of Zerda mutants was significantly less than for 
Vulpo mutants (p<0.0001). The Treg lineage remains virtually absent in older mice (1yr) 
indicating that these were persistent defects and not compensated over time (data not shown).   
 
I also observed a generalised increase in Tconv cells in the PBL of both mutants versus Wt. I 
recorded a 42.1% increase in the frequency of CD8
+ 
T cells in the PBL of homozygous 
mutant Vulpo mice compared to Wt (p=0.0078) and a 50% increase for homozygous mutant 
Zerda mice compared to Wt (p<0.0001) (Figure 2.1-2B). I recorded a 47.9% increase in the 
frequency of CD4
+ 
T cells in the PBL of homozygous mutant Vulpo mice compared to Wt 
(p=0.0037) and a 75.4% increase for homozygous mutant Zerda mice compared to Wt 
(p<0.0001) (Figure 2.1-2C). Organ dissection of spleen (data not shown) and thymus (Figure 
2.1-3) supported these findings: I observed a significant increase in absolute cell number in 
Vulpo and Zerda mutants at every stage of thymocyte maturation (see Figure 1.1-4  for an 
overall schematic of T-cell development in the thymus) compared to Wt.   In contrast to the 
difference observed in frequency of mature nTregs between the two mutants, I observe no 
significant difference between Vulpo and Zerda mutants at all stages of thymocyte maturation 
(Figure 2.1-3).   
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Both vulpo and zerda mutations show incomplete dominance as evidenced by heterozygous 
(+/-) phenotypes intermediate to the Wt (+/+) and homozygous (-/-) mutant phenotypes 
(Figure 2.1-2). This semi-dominant effect is seen on nTreg cell development and not just 
FOXP3 expression because no decrease in mean fluorescence intensity (MFI) is observed 
during flow cytometric analysis (data not shown).  
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Figure 2.1-2: Vulpo and Zerda mice have reduced nTregs & increased Tconv in PBL.  
(A) Percentage of nTregs in PBL. (B) Percentage of CD8
+
CD4
-
 cells in PBL. (C) Percentage 
of CD8
-
CD4
+
 cells in PBL. (A-C) Each symbol represents data from an individual mouse. n = 
5 for Wt (+/+), 14 for heterozygotes (+/-) and 8 for homozygous (-/-) Vulpo mutants (left 
column). n = 3 for wt, 7 for heterozygotes and 17 for homozygous Zerda mutants (right 
column). Error bars represent mean ±1 SD. A nonparametric unpaired t test (two-tailed) was 
applied: *** p < 0.001, ** p < 0.01, * p < 0.05, ns=not significant. Graphs are 
representative of at least 2 independent experiments.          
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Figure 2.1-3: vulpo and zerda mutations affect all stages of thymocyte maturation. 
Thymus dissection was performed in Wt, Vulpo and Zerda mutants. Graphs show absolute numbers for (A) CD4
-
CD8
- 
(DN), (B) CD4
+
CD8
+
 
(DP), (C) CD4
-
CD8
+
, (D) CD4
+
CD8
- 
and (E) CD25
+
Foxp3
+
CD4
+
CD8
- 
thymocytes. Each symbol represents data from an individual 
homozygous mouse thymus: Wt (n=6), Vulpo (n=5) and Zerda (n=6). A non-parametric unpaired t test was applied to compare data sets.  
 *** p < 0.001, * p < 0.05, ns=not significant. Graphs are representative of 2 independent experiments.    
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In the two-step model of nTreg cell development 
25, 118, 126
 (Figure 1.5-1), vulpo and zerda 
mutations affect both Treg precursor populations (Figure 2.1-4). Both mutations result in 
>70% reduction in frequency of proximal CD4
+
CD8
+
FOXP3
+ 
thymocytes compared to Wt 
(p<0.01) (Figure 2.1-4A) and >40% reduction in frequency of more distal 
CD4
+
CD25
+
GITR
+
FOXP3
- 
thymocytes compared to Wt (p<0.05) (Figure 2.1-4B). No 
significant difference is observed between the two mutants. vulpo & zerda mutations therefore 
block the initial TCR/CD28-mediated induction of ɣc-cytokine-responsive FOXP3- Treg 
precursor cells from immature thymocytes.  
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Figure 2.1-4: vulpo and zerda mutations affect nTreg precursor cell development in the 
thymus  
(A) Percentage of CD4
+
CD8
+
 FOXP3
+ 
precursor cells. (B) Percentage of 
CD4
+
CD25
+
GITR
+
 FOXP3
-
 precursor cells. Each symbol represents data from an individual 
mouse. Thymocytes from Wt (n=4), Vulpo (n=3) and Zerda (n=4) homozygous mutants were 
analysed. An unpaired parametric t test (two-tailed) was applied: *** p < 0.001, ** p < 0.01, 
* p < 0.05. Each graph is representative of 2 independent experiments.  
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2.2 Dominant mutations Vulpo and Zerda impair iTreg development 
Next I examined the effects of vulpo and zerda mutations on iTreg differentiation in vitro. 
Naive CD4
+ 
T cells were stimulated with increasing concentrations of plate-bound anti-CD3 
and anti-CD28 monoclonal antibodies (mAb) for 3 days in the presence of IL-2 and TGF-β to 
generate iTreg (FOXP3
+
CD8
-
CD4
+
) cells 
140
. The upregulation of FOXP3 in Wt naive CD4
+
T 
cells correlates positively with anti-CD3 dose up to 0.5µg/ml but is reduced in Vulpo 
(p<0.05) and Zerda (p<0.05) cells (Figure 2.2-1). At higher TCR stimulation (doses of anti-
CD3 >0.5µg/ml), I observe progressive impairment of iTreg differentiation in Wt cells, as 
previously reported 
141
, as well as Vulpo and Zerda cells (Figure 2.2-1). I conclude that vulpo 
and zerda mutations impede iTreg differentiation. No difference was observed between Vulpo 
and Zerda iTreg differentiation (p=0.3).  
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Figure 2.2-1: vulpo and zerda mutations affect iTreg differentiation in the periphery.  
FACS-sorted, naive CD4
+ 
splenocytes were stimulated with plate-bound anti-CD3 mAb (0-
10µg/ml) and anti-CD28 mAb (1µg/ml) for 3 days in the presence of IL-2 and TGF-β. The 
percentage of FOXP3
+
 iTreg cells was then measured for Wt, Vulpo or Zerda by intracellular 
flow cytometry. Shown are mean values ± 1SD from 3 replicates in 2 independent 
experiments. A parametric unpaired t test was applied to compare data sets: Wt versus Vulpo 
p=0.04; Wt versus Zerda p=0.02; Vulpo versus Zerda p=0.3, not significant.  
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2.3 vulpo & zerda are point mutations in the carma1 gene  
Given the similar nature of both mutant phenotypes, initial genotyping work was performed 
on Vulpo. Using a meiotic positional cloning strategy
 133
, the vulpo mutation was mapped to a 
20 mega-base pair (Mbp) region on chromosome 5, bounded by markers 128944450 and 
149044358, with a Logarithm of Odds (LOD) score of 7.2 (p<0.001) (Figure 2.3-1).  
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Figure 2.3-1: vulpo and zerda are point mutations in the carma1 gene. 
The vulpo mutation was mapped to a 20Mbp region on chromosome 5, bound by markers 128944450 and 149044358, with a LOD score of 7.2 
(p<0.001). 
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A search of the corresponding published gene list (Ensembl.org) revealed 317 candidate genes 
including caspase recruitment domain family, member 11 (card11) - more commonly known 
as carma1 - which maps to chromosome 5, base pairs 141348953-141476550. Using 
previously identified carma1 primers (Appendix 1), DNA prepared from both Vulpo and 
Zerda mutants was amplified by polymerase chain reaction (PCR) and sequenced. The 
resulting sequences were compared to the reference carma1 sequence and point mutations 
identified in exon 4 of the carma1 gene for both vulpo (C→G at base 92061) and zerda (T 
→A at base 92108) mutations. These mutations translate into the substitution of Wt 
hydrophobic Isoleucine for mutant hydrophobic Methionine at αα79 (I79M) for vulpo and the 
substitution of Wt hydrophobic Leucine for positively-charged Glutamine at αα95 (L95Q) for 
zerda (Figure 2.3-2A). Both mutations affect the Caspase Recruitment Domain (CARD) 
(αα15-105) of the CARD-MAGUK1 (CARMA1) protein (Figure 2.3-2B): an αα sequence 
conserved across mouse and human species 
127
.  
  
As newly identified alleles of a known gene, homozygous mutants are hereafter referred to as 
Carma1
vul/vul 
and Carma1
zer/zer
.  
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Figure 2.3-2: vulpo and zerda point mutations translate into single amino acid substitutions in the CARD of the CARMA1 protein. 
(A) Point mutations in exon 4 of the carma1 gene from vulpo (C→G at base 92061) and zerda (T→A at base 92108) mutant mice, and 
corresponding αα substitutions at position 79 (I79M) for vulpo and position 95 (L95Q) for zerda. (B) The structure of the CARMA1 protein. 
Functional domains: CARD, caspase recruitment domain (residues 15-105); C-C, coiled-coil domain (residues 116-439); MAGUK, membrane-
associated guanylate kinase (GuK)-like domain made up of a PDZ domain (residues 660-742), a Src homology 3 (SH3) domain (residues 766-
834), and a guanylate kinase (GuK)-like domain (residues 954-1142). The C-C domain and MAGUK region are connected by a region of 232 
amino acids designated the linker domain (residues 440-671). vulpo and zerda mutations are located in the CARD of the CARMA1 protein. 
40, 142
.  
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2.4 vulpo and zerda mutations in the carma1 gene do not affect CARMA1 
protein expression  
Western blotting revealed Wt levels of CARMA1 protein expression in the thymi of both 
Carma1
vul/vul 
and Carma1
zer/zer
 mutant mice. Thus, neither CARD mutation affects CARMA1 
protein stability (Figure 2.4-1).  
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Figure 2.4-1: Carma1
vul/vul 
and Carma1
zer/zer
 mutants express wild-type levels of CARMA1 
protein in the thymus.  
Western blot analysis of protein expression in homozygous Vulpo, Zerda and Wt thymus 
lysates using anti-CARMA mAb (top panel) and anti-ACTIN mAb (lower panel). Two 
independent samples are shown for each phenotype. This figure is representative of 3 
independent experiments.  
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2.5 Carma1
vul/vul
 & Carma1
zer/zer
 mice do not develop spontaneous 
autoimmunity 
Given the significantly reduced nTreg and increased Tconv cell populations in the periphery 
(Figure 2.1-2), it was initially surprising that Carma1
vul/vul
 and Carma1
zer/zer
 mice remained 
healthy at 1 year and showed no macroscopic signs of spontaneous autoimmune disease upon 
examination e.g. weight loss, red eyes, dermatitis, spontaneous abortion, or splenomegaly. 
Both homozygous mutants demonstrated Wt levels of circulating anti single-stranded (ss) 
DNA IgG antibodies, 90% less than MRL/Mp.lpr/lpr positive-control mice at 1 year 
(p<0.005) (Figure 2.5-1).  These results are consistent with published findings in CARMA1-
knockout (KO) mice, which demonstrate no overt autoimmunity despite the complete absence 
of nTregs and normal development of Tconv cells 
36, 143, 144
.  
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Figure 2.5-1: Vulpo and Zerda mutant mice do not develop autoimmunity. 
Enzyme-linked immunosorbent assay (ELISA) for serum anti-ssDNA IgG auto-antibodies in 1 
yr-old Wt (n=8), Vulpo (n=10), Zerda (n=8) and MRL/Mp.lpr/lpr positive control (n=6) 
female mice. The Ab levels are expressed in arbitrary ELISA units related to a standard 
positive sample, which was assigned a value of 10 arbitrary units. Serum samples were 
screened at 1/80 and positive samples titrated to endpoint. Each symbol represents data from 
1 mouse. Horizontal bars indicate the mean. Data were analysed using a nonparametric 
unpaired t test (two-tailed): ** p < 0.01, * p < 0.05. This graph is representative of 2 
independent experiments. 
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Failure to develop autoimmunity in CARMA1-KO mice was found to be due to impaired 
activation of Tconv cells as a result of intrinsic signalling defects 
36
. I measured the activation 
of Tconv cells from Carma1
vul/vul
 and Carma1
zer/zer
 mice. The percentage of Carma1
vul/vul
 
CD4
+ 
T cells expressing an activated phenotype (CD69
+
CD44
+
CD25
+
CD62L
low
), increased 
1.5-fold in response to anti-CD3/CD28 stimulation, (p=0.03) compared to a 2.3-fold increase 
in the percentage of activated Wt CD4
+ 
T cells (p=0.00004) (Figure 2.5-2). The activation of 
CD4
+
 T cells from Carma1
zer/zer
 mutants was even more impaired, as evidenced by the 
complete absence of activation following TCR stimulation (p<0.0001) (Figure 2.5-2). A 
similar effect was observed in mutant CD8
+ 
T cells from both Carma1
vul/vul
 and Carma1
zer/zer
 
mice (data not shown). These findings suggest that Carma1
vul/vul
 and Carma1
zer/zer
 mice, like 
CARMA1-KO mice, harbour a generalised TCR/CD28 activation defect in their peripheral 
Tconv cells, which would explain their lack of autoimmunity despite minimal nTregs. The 
blockade in mature nTreg development was more pronounced in Carma1
zer/zer 
compared to 
Carma1
vul/vul
 mutants (Figure 2.1-3) and we also observe a corresponding increase in the 
degree of impairment of TCR activation in Tconv cells from Carma1
zer/zer
 compared to 
Carma1
vul/vul 
mutants (Figure 2.5-2).   
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Figure 2.5-2: Vulpo and Zerda mutant mice harbour non-reactive Tconv cells.   
Percentage of activated (CD69
+
CD44
+
CD25
+
CD62L
low
) CD4
+ 
T cells before (-) and after (+) 
stimulation with plate-bound anti-CD3 and anti-CD28 mAbs for 2 days in Wt, Vulpo and 
Zerda mutant mice. Data were analysed using a nonparametric unpaired t test (two-tailed): 
*** p < 0.001, * p < 0.05, ns = not significant. This graph is representative of four 
independent experiments in which CD4
+ 
T cell activation was analysed in triplicate with 
samples pooled from 5 mice per genotype. Black error bars represent mean ±1 SD. Similar 
results are achieved upon stimulation of mutant peripheral CD8
+ 
T cells (data not shown). 
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2.6  vulpo & zerda mutations disrupt the CARMA1/Bcl-10 association 
upon TCR activation 
Upon TCR activation, CARMA1 recruits the preformed Bcl-10 – mucosa-associated 
lymphoid tissue lymphoma translocation protein 1 (MALT1) complex to the immunological 
synapse and, based on extrapolated findings from non-Treg cell studies in vitro, CARMA1 is 
thought to bind with Bcl-10 via the CARD 
127, 128
 (Figure 2.6-1). The C-terminal caspase-like 
domain of MALT1 then interacts directly with the coiled-coil (C-C) domain of CARMA1 
145
 
(Figure 2.6-1). No other proteins are known to interact with the CARD of CARMA1.  
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Figure 2.6-1: The structures of CARMA1, Bcl-10 and MALT1 proteins.  
Upon TCR activation, CARMA1 recruits the preformed Bcl-10-MALT1 complex to the 
immunological synapse.  * Based on extrapolated findings from non-Treg cell studies in vitro, 
this is thought to be via a CARMA1-CARD: Bcl-10-CARD interaction 
127, 128
. MALT1 contains 
two immunoglobulin (Ig)-like domains that mediate binding to Bcl-10 by means of a motif 
comprising a short stretch of amino acids following the CARD 
146
. The C-terminal caspase-
like domain of MALT1 is then thought to interact directly with the coiled-coil (C-C) domain of 
CARMA1 
145
. DD, Death domain; S/T rich, Ser/Thr-rich domain.   
* 
MALT1 DD Ig Ig Caspase-like 
CARMA1 
MAGUK 
CARD C-C PDZ SH3 GUK 
CARD S/T rich Bcl10 
MALT1 DD Ig Ig Caspase-like 
 * 
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To examine the effects of vulpo and zerda CARD mutations on the ability of CARMA1 to 
recruit Bcl-10 after TCR/CD28 activation, I used immunoprecipitation studies. Using phorbol 
12-myristate 13-acetate (PMA)/ionomycin-activated splenic CD4
+ 
T cells, I quantified the 
amount of CARMA1 protein co-immunoprecipitating with anti-Bcl-10 antibody by western 
blot, in Carma1
vul/vul
 and Carma1
zer/zer
 versus Wt cells (Figure 2.6-2). As expected, Bcl-10 
interacts with CARMA1 in Wt but not Carma1
vul/vul
 and Carma1
zer/zer
 activated CD4
+
 T cells 
(Figure 2.6-2).  These results suggest that the mutations in the CARD of both CARMA1-
vulpo and CARMA1-zerda proteins prevent association with Bcl-10 after TCR stimulation.    
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Figure 2.6-2: Impaired interaction of mutant CARMA1 proteins with Bcl-10. 
Bcl-10 protein was immunoprecipitated from PMA/ionomycin-activated CD4
+
 T cells then 
resolved by SDS-PAGE, electrophorectically transferred and blotted with antibodies specific 
for CARMA1 (top panel) or Bcl-10 (lower panel). Shown are lanes for Wt, Carma1
vul/vul
 (V) 
and Carma1
zer/zer
 (Z) cells. CARMA1 runs at 130kDa. Bcl-10 runs at 32kDa. Two additional, 
fainter bands are seen above Bcl-10 in each lane. Bcl-10 is known to be mono- and bi-
phosphorylated upon lymphocyte activation 
147
. These phosphorylated Bcl-10 species (P-
Bcl10) migrate slightly slower than Bcl-10 itself and are commonly observed immediately 
above the 32kDa Bcl-10 band 
148
.  
 
  
Wt V Z 
CARMA1 (130kDa) 
Bcl-10 (32kDa) 
P-Bcl-10 
 
IP:  Blot: 
α Bcl-10 α CARMA1 
α Bcl-10 α Bcl-10 
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Chapter 3: Discussion 
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3.1 Discussion and conclusions 
The balance of Treg cells and Tconv cells is key to immune homeostasis. This study 
emphasises the role of CARMA1 at the fulcrum. I report two new mutant mice, Vulpo and 
Zerda, with a profound block in the development of nTregs in the thymus, as well as impaired 
iTreg differentiation in the periphery. Despite being independently derived, the mutants 
harbour different point mutations in the CARD motif of the crucial scaffold protein, 
CARMA1. The level of CARMA1 is not affected in Carma1
vul/vul
 or Carma1
zer/zer
 mice but 
rather the mutant CARMA1 proteins are impaired in their ability to recruit Bcl-10 after TCR 
stimulation. For the first time, these findings provide genetic and in vivo evidence of a critical 
role for the CARD of the CARMA1 protein in nTreg development in the thymus, as well as in 
vitro evidence to augment our understanding of its role in iTreg differentiation in the 
periphery.   
 
CARMA1 (also known as CARD11) belongs to the MAGUK family of proteins that function 
as molecular scaffolds to assist recruitment and assembly of signalling molecules in the 
cytoplasmic membrane 
149
. Scaffold proteins have no enzymatic activity 
150
. In addition to the 
N-terminal CARD motif, CARMA1 contains several protein-protein interaction domains 
including a coiled-coil (C-C) domain, a PDZ domain, a SH3 domain, and a GuK-like domain 
(Figure 2.6-1) 
40, 142
. The structural arrangement of PDZ, SH3, and GUK domains is also 
called the MAGUK domain. The C-C domain and MAGUK region are connected by a region 
of 232 amino acids designated the linker domain. Two other mammalian homologs exist: 
CARMA2 (also known as CARD14 or Bimp2) and CARMA3 (also known as CARD10 and 
Bimp1). They share a high degree of sequence and structural homology with CARMA1 
142, 
151, 152
. All three CARMA proteins exhibit a distinct tissue distribution pattern with CARMA1 
being predominantly expressed in hematopoietic tissues such as spleen, thymus and PBLs 
142
; 
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CARMA2 is expressed only in placenta; and CARMA3 is expressed in a broad range of 
tissues but not in hematopoietic cells 
151, 152
. This distinct tissue distribution suggests that 
CARMA family members may have the same function and play similar roles in different 
tissues 
153
. Consistent with this hypothesis, ectopic expression of CARMA3 in CARMA1-
deficient T cells effectively rescues the defect in TCR-induced NF-κB activation 154. 
   
nTreg development is known to require an intricate set of signalling events, most notably 
engagement of the TCR and stimulation by IL-2 
25
. The TCR and IL-2 signals regulate the 
generation of nTreg precursors and their subsequent maturation, respectively 
118, 126
. 
Activation of the transcription factor NF-κB pathway is known to be particularly important in 
nTreg development, more so than for Tconv cells, as deficits in elements linking the TCR to 
NF-κB have proven deleterious for Treg development 29. Mice with conditional knockout of 
protein kinase C theta (PKC-θ), Bcl-10, CARMA1 or IKK2 are deficient in nTregs 36, 144, 155 
and prior to my work, CARMA1 was already thought to play a Treg cell-intrinsic role in both 
the initial TCR/CD28 activation step and the subsequent IL-2 receptor signalling maturation 
step of nTreg development 
36, 156
.  
 
In brief, TCR/CD28 stimulation of immature thymocytes by MHC class II-peptide complexes 
on APCs induces the formation of the immunological synapse (IS). It is hypothesised that 
inactive CARMA1 exists in an autorepressed conformation 
157
. The linker region between the 
C-C and MAGUK domains blocks the homotypic interaction of the CARD motifs by binding 
to the N-terminus of CARMA1 
158
. Upon ligation of the TCR and CD28 co-receptor, 
CARMA1 is recruited to the IS together with PKC-θ which mediates a series of 
phosphorylation events in the linker region of CARMA1 between the C-C and PDZ domains, 
reducing intramolecular affinity for the CARD domain 
144
. This liberates the CARD and 
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coiled-coiled domains, enabling B cell CLL/lymphoma 10 (Bcl-10) and mucosa associated 
lymphoid tissue lymphoma translocation gene 1 (MALT1) recruitment, and CARMA1-Bcl10-
MALT1 (CBM) signalling complex formation 
154, 159
. The CC domain of CARMA1 is thought 
to mediate oligomerisation and association with the preformed Bcl10-MALT1 complex, 
which appears to be constitutively expressed in the cytoplasm 
160
. The C-terminal caspase-like 
domain of MALT1 also binds directly to the C-C domain of CARMA1 in a Bcl-10 
independent manner and so, MALT1, Bcl-10 and CARMA1 form a tri-molecular complex 
145
. 
The function of the MAGUK domain remains unclear; however, mutation studies suggest that 
the SH3 domain regulates the membrane localisation of CARMA1 
161
. 
 
The CBM complex recruits TNF receptor-associated factor 6 (TRAF6) that catalyses the 
ubiquitination of itself and MALT1, and these ubiquitin chains provide the docking sites for 
TGF-β activated kinase 1 (TAK1) and the inhibitor of NF-κB (IκB) kinase (IKK) complex 
recruitment 
162
. The NF-κB inhibitor, IκBα, is then degraded, unmasking the nuclear 
localisation sequence of NF-κB which can then be rapidly translocated into the nucleus to 
begin transcription of its target genes 
153
. The NF-κB subunit c-Rel has been shown to bind to 
enhancer sequences located in the promoter and third intron of the Foxp3 gene, and plays a 
direct role in Foxp3 expression during Treg cell development 
39, 163-165
. In addition to 
phosphorylating IKKβ leading to the activation of NF-κB, TAK1 also phosphorylates 
mitogen-activated protein kinase kinase (MAP2K) which in turn activates the JNK signalling 
pathway 
166
. c-Jun is the main target of the JNK signalling pathway 
167
, and forms a 
heterodimer with activating transcription factor (ATF) 2 to activate transcription of FOXP3 
168
.  
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As I mention earlier in this thesis, two precursor populations of thymic Tregs have been 
described. The most proximal CD4
+
CD8
+
Foxp3
+
 thymocyte population can develop into 
mature nTreg cells if transferred into recipient hosts 
125
. The more distal 
CD4
+
CD25
+
CD122
+
GITR
+
 precursor cell population lacks FoxP3 expression until exposed to 
IL-2 without further TCR stimulation 
126
.  Whether the proximal precursor gives rise to the 
distal one prior to mature Treg cell generation is not known. In 2009, Molinero et al published 
their observations that the CARMA1 protein is required for the development of both these 
known Treg precursor cell populations via the TCR-CBM-NF-κB axis, and therefore 
suggested that CARMA1 was unlikely to also play a role in the second IL-2 -dependent step 
of Foxp3
-
 nTreg precursor cell maturation in to mature nTreg cells 
36
. But, later that year Lee 
et al revealed a critical role for CARMA1 in regulating the IL-2-stimulated maturation of 
CD4
+
CD25
+
CD122
+
GITR
+
Foxp3
- 
nTreg precursor cells  
156
, and showed that IL-2 stimulates 
strong tyrosine phosphorylation of STAT5 in Wt thymocytes but not CARMA1
-/- 
thymocytes 
156
. STAT5 is known to have binding sites within the Foxp3 promoter 
116, 121
. They showed 
that this signalling defect was unlikely due to the blockade of typical NF-κB activation 
because competent IL-2 receptor signalling was detected in IκBα∆N transgenic thymocytes 
despite their lack of NF-κB activation 156. 
 
To-date, it has always been assumed that in the process of nTreg development, CARMA1 and 
Bcl-10 interact via their CARD motifs. This assumption is based on results from co-
transfection studies in unstimulated, non-Treg cell lines 
127, 128, 151, 152, 161, 169
 and TCR 
stimulation with non-physiological ligands in murine Tconv cells 
148
. In 2003, Newton & 
Dixit generated knock-in mice expressing a CARD-less form of CARMA1 but the impact of 
this mutation on the specific Bcl-10: CARMA1 interaction was never reported 
170
.  In addition 
to CARMA1-KO mice 
36, 143, 171, 172
, two other CARMA1 mutant mice have been described: 
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Unmodulated mice which have a L298Q substitution in the C-C domain 
173
  and 
Carma1
king/king
 mice which have a L525G substitution in the linker domain 
144
. The 
CARMA1-king protein is degraded due to instability 
144
 and Unmodulated mice develop 
intense dermatitis and atopy by 10 weeks of age 
173
. By definition, not one of these mutants is 
able to provide in vivo evidence of CARD-CARD binding of CARMA1 and Bcl-10 in nTreg 
cell development. For the first time, I show that the CARD of CARMA1 is required for TCR-
mediated signals triggered by physiological self-MHC ligands in thymic nTreg development.  
 
I present two new, in vivo models, Vulpo and Zerda, both expressing Wt levels of mutant 
CARMA1 protein. These mutants remain healthy at 1 year, do not develop spontaneous 
autoimmune disease and have allowed the identification of critical residues in the CARD that 
mediate CARMA1 function in T cell activation and Treg development. Using co-
immunoprecipitation studies to examine the CARMA1: Bcl-10 interaction in activated CD4
+ 
T cells from Vulpo and Zerda mutant mice, I demonstrate complete impairment of CARMA1: 
Bcl-10 binding in both mutants. I believe that this experiment in which I resolve by SDS-
PAGE and electrophorectically transfer a range of Bcl-10 protein concentrations up to a 
maximum of 500µg/ml total protein, probe with maximum concentration anti-CARMA1 mAb 
[1:1000] and then incubate with protein A-HRP in place of secondary Ab for improved 
protein detection avoiding heavy and light chain signals 
174
, prior to film exposure for up to 3 
hours, gave me the best opportunity to detect any difference in CARMA1: Bcl-10 binding 
between Vulpo and Zerda mutants. I found none. I did not repeat the experiments using 
heterozygote mice because this would not affect the affinity of mutant CARMA1 for a 
binding partner but would rather just increase the amount of Wt CARMA1 protein binding. 
Therefore, I conclude that, as far as I can observe, the vulpo and zerda CARD mutations both 
completely impair the association of Bcl-10 with CARMA1.  
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Given that downstream NF-κB and JNK signalling is completely dependent on CARMA1: 
Bcl-10 binding in thymic nTreg development, I use CARMA1: Bcl-10 binding as an analogue 
for NF-κB and JNK signalling after TCR stimulation and conclude that carma1-vulpo and -
zerda mutations, like Bcl-10
-/- 
and carma1
-/-
 mutations 
36, 144, 155
, result in complete 
downstream impairment of NF-κB and JNK signalling in nTreg cell development.  In the two-
step model of nTreg cell development, I demonstrate a role for the CARD of CARMA1 in the 
TCR/CD28-mediated induction of c-cytokine-responsive FOXP3- nTreg precursor cells from 
immature thymocytes.  
 
I observe significant differences in the frequency of mature FOXP3
+ 
nTregs (Figure 2.1-3), 
and also in Tconv cell activation (Figure 2.5-2), between Vulpo and Zerda mutants. In both 
cases, the zerda mutation results in a more profound phenotype. Despite this, both mutations 
result in complete impairment of Bcl-10: CARMA1 binding and presumed downstream NF-
κB and JNK signalling during nTreg cell development. Therefore, I conclude that my findings 
suggest a Bcl-10-independent role for the CARD of CARMA1 in TCR signalling during 
nTreg development. CARD motifs are characterized by their conserved structures containing 
six helices 
158
. They possess acid and basic patches on different sides and the interaction of 
CARDs requires amino acids with opposite charges 
158
. Unlike the I79M vulpo mutation, the 
L95Q zerda mutation results in an amino acid charge change from hydrophobic Leucine to 
positively-charged Glutamine in the CARD and it is likely that this charge change is 
responsible for the more severe phenotype observed in Zerda compared to Vulpo mutant 
mice, through as yet unknown alterations in protein: protein interactions. In addition to its role 
in the NF-κB and JNK pathway-mediated generation of FOXP3- nTreg precursor cells from 
immature thymocytes, CARMA1 has recently been shown to play a critical role in the IL-2R 
signalling pathway-mediated maturation of these precursor cells into mature FOXP3
+ 
nTregs 
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156
. How the CARMA1 protein is integrated into this pathway to drive these events is yet to be 
defined. I suggest that the CARD of CARMA1 facilitates this IL-2R-mediated maturation 
stage of nTreg development, and that it is the different effects of vulpo and zerda mutations 
on this role that accounts for the differences observed between their phenotypes.  
 
To the best of my knowledge, vulpo and zerda mutations only affect the amino acid sequence 
of the CARD of CARMA1. Since the CARD motifs are protein interaction modules, their 
surface features dictate their mode of interactions with their binding partners and my results 
suggest that vulpo and zerda mutations impair CARMA1’s CARD interaction with its binding 
partner. However, I recognise that it is a formal possibility that the mutations that affect 
CARD function may also alter the conformation of non-CARD domains in CARMA1.  
 
In contrast to the high dependency on TCR-CARMA1-NFB activity for thymic development 
of nTregs and their precursors, TCR-CARMA1-NFκB activity is thought to be dispensable 
for iTreg induction in the periphery 
144
. In agreement with published findings in CARMA1-
KO cells 
36, 144, 155
, Vulpo and Zerda CARMA1 mutants retain some differentiation of naive 
CD4
+ 
T cells into iTregs at low dose TCR stimulation, supporting a role for the CARMA1-
independent TGFβ-TAK1-JNK signalling pathway in iTreg differentiation. TGFβ does not 
play a role in the thymic selection of nTregs and so, we assume nTreg precursors are 
dependent on CBM-TRAF6 for TAK1 activation 
29
. However, as observed in CARMA1-KO 
cells 
140
, Carma1
vul/vul
 and Carma1
zer/zer
 CD4
+ 
T cells are less sensitive to increasing 
concentrations of anti-CD3 and upregulate FOXP3 less rapidly when compared to Wt naive 
CD4
+ 
T cells. I suggest that despite adequate CARMA1-independent TGFβ-TAK1-JNK 
signalling, the increased sensitivity offered by the anti-CD3 dose-dependent induction of 
TCR-CARMA1-NFB/JNK activity in Wt CD4+ T cells is absent in Carma1vul/vul and 
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Carma1
zer/zer
 CD4
+ 
T cells, as well as CARMA1-KO cells. I propose that TCR-CARMA1-
NFB activity is only partially dispensable for iTreg induction at low dose TCR stimulation 
in the periphery.  
  
Strong TCR stimulation prevents conversion of naive T cells into iTregs and overrules the 
ability of TGFβ/IL-2 to drive FOXP3 expression141, although the molecular mechanisms by 
which FOXP3 expression is inhibited are not well understood. Of note, TAK1 overexpression 
has recently been shown to restrain CARMA1-dependent activation of NF-κB by reducing 
Bcl-10 levels which may be relevant 
166
.  CARMA1-KO CD4
+ 
T cells are partially resistant to 
this high-dose TCR-mediated inhibition of iTreg differentiation suggesting that NF-κB 
abrogates FOXP3 induction upon high TCR stimulation
140
. In contrast Carma1
vul/vul
 and 
Carma1
zer/zer
 CD4
+
T cells retain sensitivity to this high TCR-induced abrogation of iTreg 
differentiation. These data support the view of Molinero et al 
140
 that high-dose TCR-
mediated inhibition of iTreg differentiation is at least in part NF-κB dependent, but I propose 
that this negative regulation is not via the conventional CARD-dependent TCR-CBM-NFB 
axis but via a novel MAGUK region-dependent TCR-protein kinase C-delta (PKCδ)-
CARMA1 signalling pathway 
175
. Endogenous PKCδ has recently been shown to be recruited 
to the MAGUK region of CARMA1 after CD3/CD28 costimulation in a dose-dependent 
manner where it inhibits the interaction between MALT1 and TRAF6, but not the association 
of CARMA1 with PKCθ, Bcl-10 or MALT1 175. Unlike CARMA1-KO cells, the MAGUK 
region of CARMA1 is preserved in CARMA1-vulpo and CARMA1-zerda proteins and so I 
predict that PKCδ-mediated inhibition of TCR signalling remains intact in Vulpo and Zerda 
CARD mutants.  
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Therapeutic targeting of the conserved canonical NF-κB signalosome is difficult due to its 
ubiquitous functions and multiple inputs. By contrast, due to its non-redundant role in 
antigen-receptor activation and its specificity to signals from the antigen-receptors, CARMA1 
is a unique and appealing target for the design of therapeutic interventions that promote 
immune tolerance. For the first time, this work provides two healthy in vivo models, Vulpo 
and Zerda, in which to further study the interactions of the CARMA1 protein with its binding 
partners and contribute to the goal of expounding the essential pathways required for Treg cell 
development.   
 
3.2 Critique of Methods 
Technological advances have changed how biological systems are studied and created 
scenarios where entire genomes can be sequenced in relatively short time frames. However, 
progress in understanding complex networks, and the functionality of their components has 
been far slower. Forward genetics is an extremely powerful tool because of its exploratory 
nature; with no bias or a priori knowledge required about the pathways involved in a process. 
In addition, ENU mutagenesis causes point mutations that can lead to amorphic, 
hypomorphic, hypermorphic, neomorphic, as well as conditional mutations; potentially 
obviating the pitfall of genetic redundancy or lethality. This variety of mutations far exceeds 
what is possible with biological mutagens, like T-DNA or transposons, which typically lead 
to amorphic alleles. Point mutations can also be informative with respect to the domain 
structure of the affected gene product, as is the case in this project.  
 
However, this work also highlights some of the limitations of a forward genetic approach to 
gene identification. Seen by some as an expensive, labour- and animal- intensive, “scattergun” 
approach, the strength of forward genetics lies in the phenotypic screen which must be simple, 
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rapid (the process is often slow and laborious), reliable (based on strong wild-type phenotypes 
to reduce the number of false negatives) and the standard deviations for each parameter must 
be as small as possible so “cut off values” can be defined and the isolation of false positives 
minimised. Nevertheless, overlap of function is exceedingly common and many phenotypic 
differences prove to be polygenic, limiting the effectiveness of phenotypic screens 
25
. When 
an isolated phenotypic mutation has been identified and confirmed to affect the germline, a 
stable mutant stock must be established and the job of genotyping commenced.  The 
traditional positional cloning approach I used to genotype the Vulpo mutant phenotype can be 
criticised for being tedious and time-consuming and indeed, had this approach not worked, 
whole genome sequencing could have been performed in less time but at significant additional 
cost.  
 
When I describe the forward genetic approach in my Introduction, I state “…genotyping and 
phenotyping are usually performed in parallel, until the identity of the affected gene is 
required for a more thorough in-depth phenotyping 
133.” This is theoretically true but leads me 
to highlight the greatest hazard of forward genetics: the exploratory, unbiased nature of this 
approach will identify known, as well as novel, genes that are responsible for a given 
phenotype. Thus, extensive characterisation of a mutant phenotype prior to identification of 
the affected gene could prove to be an inefficient use of research funds. Although this project 
may be the first demonstration that mutations in the CARD of CARMA1 affect nTreg 
development in vivo, it could be argued that my findings are predictable based on prior studies 
of CARMA1-KO mice and in vitro assays of CARMA1 mutations. This detracts significantly 
from the novelty of my work.  
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Based upon my experience, I would suggest that the forward genetic approach to gene 
identification may be better suited to large scale operations and two such ENU mutagenesis 
centres are currently in operation at the Institute of Human Genetics in Munich, Germany and 
MRC Harwell, UK. These mutagenesis programmes generate and characterise a large and 
functionally diverse set of mouse mutant lines that go into multi-parameter phenotypic 
screening programmes looking for different dominant and recessive mutations on behalf of 
different research groups. Whilst this approach may be less “targeted”, it generates a higher 
result yield with decreased outlay of labour, time and research funds.  
 
3.3 Future work 
In the two-step model of nTreg cell development, I demonstrate a critical role for the CARD 
of CARMA1 in the TCR/CD28-mediated induction of c-cytokine-responsive FOXP3- Treg 
precursor cells from immature thymocytes, and I propose a new Bcl-10/JNK/NF-κB-
independent role for the CARD of CARMA1 in the IL-2R-mediated maturation of FOXP3
- 
Treg precursor cells into mature FOXP3
+
 nTreg cells. Future characterisation of the IL-2R 
signalling pathway in the context of nTreg maturation, and confirmation of the proposed role 
for CARMA1 therein, are required in order to substantiate my hypothesis. Vulpo and Zerda 
mutant CARMA1 mice will allow determination of how CARD function influences IL-2R 
signalling in nTreg development.  
 
To the best of my knowledge, vulpo and zerda mutations only affect the amino acid sequence 
of the CARD of CARMA1. Since the CARD motifs are protein interaction modules, their 
surface features dictate their mode of interactions with their binding partners and my results 
suggest that vulpo and zerda mutations impair CARMA1’s CARD interactions with its 
binding partners. However, in my discussion, I recognise that it is a formal possibility that the 
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mutations that affect CARD function may also alter the conformation of non-CARD domains 
in CARMA1. To that end, in collaboration with experts from the Division of Molecular 
Biosciences, it would be pertinent to establish the effects of vulpo and zerda point mutations 
on the overall structure of CARMA1-Vulpo and CARMA1-Zerda mutant proteins in both 
activate and inactive states. Several online protein structure prediction tools exist e.g.  
"Phyre2” (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) but obtaining and 
purifying CARD motifs in vitro for molecular analysis is known to be notoriously difficult 
due to their self-aggregation under physiological conditions and sensitivity to pH and salt 
concentration 
176
.  Aside from Bcl-10, no other proteins are known to interact with the CARD 
of CARMA1. For this reason, I did not study the effects of vulpo and zerda mutations on 
CARMA1’s interactions with its other known binding partners such as MALT1 and TRAF6. 
However, insights into the overall effects of vulpo and zerda mutations on CARMA1 protein 
structure may prompt me to revisit this.  
 
The supreme aim of this work was to identify novel genes responsible for the development of 
nTreg cells in the thymus. To that end, I did not study the effects of Vulpo and Zerda mutants 
on other cell lineages. However, CARMA1 is known to be expressed in all lymphoid cells 
150, 
170
 and to play a role in the activation of B cells and natural killer cells, as well as T cells 
150
. 
Recent work seems to suggest that CARMA9 plays the role of CARMA1 in myeloid cells 
157
. 
Therefore, it would be interesting to analyse the effects of vulpo and zerda mutations on the 
frequency of these cells compared to Wt, by staining with appropriate conjugated mAbs 
followed by flow cytometric analysis.    
 
Finally, we know that Carma1
vul/vul
 and Carma1
zer/zer 
mutant mice do not develop spontaneous 
autoimmune disease despite their lack of nTregs and increased frequency of Tconv cells. This 
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is explained by the generalised activation defect observed in their Tconv cells. With this in 
mind, it would be interesting to examine the response of Carma1
vul/vul
 and Carma1
zer/zer 
mutant mice to induced T cell-dependent autoimmune disease. However, selecting a disease 
model that would allow accurate conclusions to be drawn and enhance our understanding of 
the role of CARMA1 in immune homeostasis is difficult. Given my renal background, I 
briefly explored the possibility of using an accelerated nephrotoxic nephritis (NTN) model but 
the induced kidney inflammation is immune complex-mediated with complement, 
macrophages and receptors for the Fc portion of IgG playing a key role. Although it is 
considered a T helper 1 cell-mediated process, it would not allow me to test iTreg or antigen-
specific T cell stimulation. The experimental autoimmune encephalomyelitis model is a T-cell 
mediated inflammatory process and may be a more appropriate disease model to study. Expert 
guidance is required.   
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Chapter 4: Materials and Methods 
  
  
 
99 
4.1 Materials 
 
Reagent Formulation 
Ethylene diamine tetra-acetate (EDTA) 0.5M EDTA, pH 8.0 
Phosphate Buffered Saline (PBS) (10x)  
pH 7.5 
136mM NaCl (80g); 3mM KCl (2g); 8mM 
Na2HPO4 (29g); 1.5mM KH2PO4 (2g); make 
up to 2l with ddH2O. 
FACS buffer (4°C) 0.5% albumin bovine serum (BSA) in PBS 
10% sodium dodecyl sulphate (SDS) 10% w/v SDS, pH 7.0 
DNA lysis buffer  50mM Tris-HCl, pH8.0; 100mM EDTA; 
100mM NaCl; 1% SDS. 
TE buffer (Genomic DNA Buffer) 10mM Tris-HCl, pH 8.0; 0.1mM EDTA.  
TAE buffer (50x) 242g Tris-base, 57.1ml glacial acetic acid, 
18.6g EDTA 
MACS buffer (4°C) 0.5% BSA, 2mM EDTA; made up in PBS 
(1x). 
FACS sorting buffer (4°C) 9.6ml HBSS (calcium, magnesium & phenol 
red free); 200µl 1M HEPES buffer (20mM); 
100µl FBS (1%); gentamicin. 
FACS collecting buffer (4°C) 8.9ml HBSS, 200µl 1M HEPES buffer 
(20mM); 1ml FBS (10%); gentamicin. 
 
Table 4.1-1: List of general stock solutions used for this work 
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Table 4.1-2: List of reagents used for SDS-PAGE gels 
  
Acrylamide gels: 10% 5% stacking 
Buffer - lower 8ml - 
Buffer - upper - 5ml 
30% stock acrylamide (4°C) 10.4ml 3ml 
ddH2O 13.4ml 12ml 
10% ammonium persulphate (aliquots 
stored at -20°C) 
200µl 100µl 
Tetramethyl-ethylenediamine 
(SIGMA)  
50µl 40µl 
  
 
101 
 
Solutions Formulation 
Lower buffer 750ml 2M Tris-HCl pH 8.8; 250ml ddH2O; 
4g SDS.  
Upper buffer 500ml 1M Tris-HCl pH 6.8; 500ml ddH2O; 
4g SDS. 
Laemmli buffer (2x concentrate) (-20°C) Sigma-Aldrich 
S23401 
Running buffer (4°C) 60.6g Tris Base; 288g Glycine; 20g SDS; 
make up to 2l with ddH2O; pH 8.2. 
Electro-transfer buffer (EB) (50x) 60.6g Tris Base; 288g Glycine; make up to 2l 
with ddH2O.  
Electro-transfer buffer (1x) 40ml EB (50x); 400ml methanol; make up to 
2l with ddH2O. 
10% Tween/PBS 10ml Tween 20; 90ml PBS (1x). 
Wash buffer: 0.1% Tween/PBS 20ml 10% Tween/PBS; 1980ml PBS (1x) 
Blocking buffer: 5% milk/0.1% Tween PBS 
(4°C)  
10g Marvel skimmed milk powder, 200ml 
0.1% Tween/PBS.  
 
Table 4.1-3: Composition of reagents used for SDS-PAGE  
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Antibody (Ab) Application Origin Distributor 
CARD11 (1D12) 
#4435 
(-20°C) 
Western blotting 
([1:1000] in 5% 
milk/0.1% Tween 
PBS). 
Rabbit mAb 
prepared from 
animals immunised 
with a synthetic 
peptide 
corresponding to 
residues surrounding 
threonine 195 of 
CARD11.  
Cell Signaling 
Technology 
Beta-Actin 
Ab6276 
(4°C) 
[1:10,000] in 5% 
milk/0.1% Tween PBS 
Mouse mAb to N-
terminal of beta 
isoform of actin 
Abcam 
Bcl10 (H-197) 
Sc-5611 
(4°C) 
Western blotting 
[1:1000] in 5% 
milk/0.1% Tween 
PBS); 
immunoprecipitation 
(2µg per 100-500µg of 
total protein in 1ml 
cell lysate) 
Rabbit polyclonal Ab 
raised against amino 
acids 1-197 mapping 
at the N-terminus of 
Bcl-10 of human 
origin. 
Santa Cruz 
Biotechnology 
 
Table 4.1-4: List of primary antibodies used for experiments.   
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Immunoprecipitation Reagents Distributor 
Protease Inhibitor Cocktail. 
Used at [1:100] unless otherwise stated. 
(4°C) 
Sigma-Aldrich 
P8340 
RIPA buffer 
(4°C) 
Sigma-Aldrich 
R0278 
Bio-Rad protein assay kit II with BSA 
standard for total protein quantification 
BIO-RAD 
500-002 
Protein A/G PLUS-Agarose 
(4°C) 
Santa Cruz Biotechnology 
sc-2003 
Protein A-peroxidase (Protein A-HRP). Used 
as secondary Ab in co-immunoprecipitation 
experiments for improved western blotting 
detection to avoid heavy and light chain 
signals. Used at [1:2500]. (4°C) 
Sigma-Aldrich 
P8651 
 
Table 4.1-5: List of reagents used for immunoprecipitation experiments.   
 
Hybond-ECL 0.45µm GE Healthcare Amersham 
Hyperfilm-ECL 18x24cm GE Healthcare Amersham 
ECL Western Blotting Detection Reagents GE Healthcare Amersham 
 
Table 4.1-6: Additional materials used for Western Blotting. 
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Reagent Application Distributor 
Complete RPMI 1640 medium  
(4°C) 
Cell culture Invitrogen GIBCO 
#31870-025 
Heat-inactivated fetal bovine 
serum (-20°C) 
Used to supplement RPMI 
for cell culture 
Invitrogen GIBCO 
#10437028 
Penicillin/Streptamycin/Glutamine 
(P/S/G) (100x) (-20°C) 
Used to supplement RPMI 
for cell culture 
Invitrogen GIBCO 
#10378-016 
Hanks’ Balanced Salt Solution 
(HBSS) – calcium, magnesium & 
phenol red free 
Cell preparation for sorting 
by flow cytometry 
Invitrogen GIBCO 
#14175046 
 
Goat serum 
(-20°C) 
For staining samples for 
cell sorting by flow 
cytometry 
Invitrogen GIBCO 
#16210-064 
Gentamicin solution  
(4°C) 
Cell preparation for sorting 
by flow cytometry. Heat 
and pH stable compared to 
P/S/G 
Sigma-Aldrich 
#G1272 
Anti-mouse CD28 
 
Cell stimulation. Used at 
1µg/ml unless otherwise 
stated. 
eBioscience 
#16-0281-86 
Anti-mouse CD3 
 
Cell stimulation. Used at 
2µg/ml unless otherwise 
stated. 
eBioscience 
#16-0032-86 
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recombinant mouse IL-2  
(-80°C) 
Cell stimulation. Used at 
10units/ml unless 
otherwise stated. 
BD Bioscience 
#356078 
Mouse Transforming Growth 
Factor β1 
(-80°C) 
Cell stimulation. Used at 
2.5ng/ml unless otherwise 
stated. 
Cell Signaling Technology 
#5231-LC 
Ionomycin, Calcium salt 
(-20°C) 
 
Cell stimulation. Used at 
300ng/ml unless otherwise 
stated. 
Cell Signaling Technology 
#9995 
Phorbol-12-Myristate-13-Acetate 
(PMA) 
(-20°C) 
Cell stimulation. Used at 
200ng/ml unless otherwise 
stated. 
Calbiochem 
#524400 
Mouse CD4 (L3T4) microbeads 
(4°C) 
MACS cell sorting. 10µl 
per 10
7 
cells. 
Miltenyi Biotech 
#130-041-201 
MACS separation columns (LS) MACS cell sorting. Max 
10
9 
cells per column.  
Miltenyi Biotech 
#130-042-401 
 
Table 4.1-7: List of reagents used for cell culture experiments.   
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ELISA Reagent Formulation 
Borate Buffered Saline (BBS) 30.92g boric acid [100mM]; 47.68g Na-tetraborate.10H2O 
[25mM] = Borax (anhydrous 25.15g); 21.92g NaCl 
[75mM]; make up to 5l with ddH2O; pH 8.3-8.5.  
PBS 0.5% BSA NaN3 1g BSA; 400µl NaN3 10%; make up to 200ml with PBS. 
PBS 2% BSA Tween-20 NaN3 4g BSA; 400µl NaN3 10%; 1ml Tween-20 10% (2ml 
Tween-20 + 18ml PBS, add 40 µl NaN3 for storage); make 
up to 200ml with PBS. 
Substrate: 
p-Nitrophenyl phosphate  tablet 
sets dissolved in ddH2O. Used at 
50µl/well.  
Sigma-Aldrich 
#N-2770 
 
Table 4.1-8: List of reagents used for Enzyme-linked immunosorbent assay (ELISA). 
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4.2  Methods 
4.2.1 Mice  
Mice were bred in Central Biomedical Services (Imperial College London, UK) and kept 
under specific pathogen-free conditions. All animal work performed as part of this project 
was authorised by the Home Office under the Animals (Scientific Procedures) Act 1986, 
License PPL 70/6490. Individual mice were identified by numeric ear tagging. The 
MRL/Mp.lpr/lpr mouse serum samples were provided by Professor Marina Botto (Imperial 
College, London. UK). Homozygous mutants were used for all experiments unless otherwise 
stated. 
 
4.2.2 N-ethyl-N-nitrosourea mutagenesis 
N-ethyl-N-nitrosourea (ENU) mutagenesis was used to generate random mutations in the 
sperm of C57BL/6J (Charles River sub-strain) male mice, generation (G) 0. G0 mice were 
bred to C57BL/6J wild-type (Wt) females to obtain G1 mice derived from an ENU-mutated 
sperm with a unique spectrum of point mutations (~2,500 heterozygous mutations per G1)
177
. 
The production and maintenance of many thousands of mutant mice demand that a wide 
variety of screens be applied to the animals; otherwise the cost cannot be justified. Drs Sophie 
Rutschmann and Onjee Choi set up and executed the ENU mutagenesis and breeding 
programme in our laboratory, supported by a Medical Research Council grant.  
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4.2.3 Phenotypic screen 
Tail vein blood samples (50μl) were taken from 6-wk old heterozygous, G1 ENU mutant mice 
and analysed by flow cytometry to identify mutants with abnormal nTreg cell development, 
defined as a CD25
+
FOXP3
+
/CD4
+ 
cell population out with 2 SD of the mean.  
 
4.2.4 Cell preparation and flow cytometry 
Cells were treated with red blood cell (RBC) lysis buffer (Santa Cruz Biotechnology, SC-
296258) and then 25μl of anti-mouse Fcγ-R (CD16/32) antibody (eBioscience, UK) added at 
a final concentration of 1/20 for 10 minutes at room temperature, to block non-specific 
antibody binding. Cells were subsequently stained with conjugated monoclonal antibodies for 
30 minutes at 4°C. All anti-mouse antibodies were applied to a 1/200 final dilution and from 
eBioscience, UK, unless stated: PerCP-Cy5.5 conjugated anti-CD4, PB conjugated anti-CD8 
(BD Biosciences), PeCy7 conjugated anti-CD25, FITC conjugated anti-B220 (BD 
Biosciences), APC conjugated anti-CD44, APC conjugated anti-GITR, FITC conjugated anti-
CD62L (BD Biosciences), PE conjugated anti-CD69 (PharMingen). Cells were then washed 
by centrifugation in FACS buffer for 2 minutes at 2100 rpm and 100μl of 
Cytofix/Cytoperm™ (BD Biosciences) applied for 20 minutes at 4°C, in order to permeabilise 
the cells prior to intracellular staining with FITC conjugated anti-Foxp3, as per 
manufacturer’s protocol. All samples were acquired on a DAKO Cyan 9 flow cytometer and 
the data analysed with Summit
TM
 software (DAKO). 
 
4.2.5 Organ dissection 
Mice were culled using appropriate methods of humane killing as described in Schedule 1 
(revised February 1997) of the Animals (Scientific Procedures) Act 1986. Death was 
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subsequently confirmed. The animal was then positioned ventral side uppermost on a 
dissecting board and pinned in a spread-eagle position through the fore-and hind-feet. Using 
aseptic technique, thymus and spleen were harvested according to the anatomical map 
described in (Figure 4.2.5-1) via a midline, ventral incision and collected in 5ml Complete 
RMPI medium on ice. Using forceps, organs were ground through nylon mesh to make a 
single-cell suspension and then centrifuged at 1600 rpm for 5 minutes at 4°C. The medium 
was poured off and spleen suspensions re-suspended in 2ml RBC lysis buffer for 2 minutes. 
The reaction was stopped with 8ml RPMI medium and the sample once again centrifuged at 
1600 rpm for 5 minutes at 4°C. The medium was poured off and RBC lysis repeated. Finally 
RBC lysed spleen suspensions and original thymus suspensions were re-suspended in 10ml 
fresh RPMI medium ready for subsequent experiments. 2µl samples were removed for 
staining with trypan blue and cell counting (viable and total cell counts) by haemocytometer.  
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Figure 4.2-1: A general picture of the morphological characteristics of every lymph node 
and its localization in the normal mouse. 
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4.2.6 Confirmation of mutation heritability and breeding 
Heterozygote G1 phenodeviants with abnormal nTreg development were examined to 
determine whether the phenotype was heritable: G1 phenodeviants were crossed with Wt 
mice and the G2 population screened for 50% expression of deviant phenotype. Once 
transmissibility was confirmed, each nTreg mutation was bred to homozygosity. I was 
assisted with breeding by my laboratory colleague, Dr Lihui Wang.   
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4.2.7 Genotyping 
To identify the causative genetic mutations underlying these heritable nTreg phenodeviations, 
I adopted a classical positional cloning strategy (Figure 4.2-2). Heterozygote nTreg 
phenodeviants were outcrossed to phylogenetically-distinct inbred Wt 129Sv1mJ mice 
(Charles River sub-strain). The resulting hybrid (H) 1 generation mice were screened for 
abnormal nTreg development, as previously described, and affected H1 mice crossed with the 
Wt 129Sv1mJ animal again. The H2 offspring were phenotyped and tail DNA prepared from 
each mouse (Appendix B). Samples were sent to LGC Genomics (formerly KBioscience) for 
genotyping against 358 single nucleotide polymorphisms (SNPs), which differ between 
C57BL/6 and 129/SvJ mice (Appendix C). The meiotic recombination frequency between the 
SNPs and the mutation was calculated and a Logarithm of Odds (LOD) scored 
133
.  The LOD 
score is the log base 10 of the likelihood ratio under the hypotheses of linkage and non-
linkage:  
    θ (# of recombinants) • (1 – θ) (# of nonrecombinants) 
LOD score = Z =  log10  
    (0.5) 
(# of recombinants) 
(0.5)
 (# of nonrecombinants)
  
 
 
 
A LOD score can be converted into an equivalent chi-squared statistic with the following 
simple formula:  
 
T = 2 ln (10) Z  
And so it can be assumed that Z = 3, p=0.001 
 
i.e. A LOD score >3 strongly indicates linkage.  
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Figure 4.2-2: Diagram illustrating the classical positional cloning strategy adopted to 
identify causative mutations.  
C57BL/6 heterozygote (+/-) nTreg phenodeviants were outcrossed to Wt (+/+) 129Sv1mJ 
mice. The resulting hybrid (H) 1 generation mice were screened for abnormal nTreg 
development and affected H1 mice crossed with the Wt 129Sv1mJ animal again. The H2 
offspring were phenotyped for abnormal nTreg development. […] = phenotype 
 
 
 
 
  
 H1 
 
129/SvImJ +/+ 
      [Wt] 
C57BL/6 +/- 
[mutant] 
    
 
 
  
129/SvImJ +/+ [Wt] 50% [mutant] 50% [Wt] 
    
 
 
[mutant] [mutant] [Wt] [Wt] 
        
 
H2 
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4.2.8 carma1 sequencing 
All coding exons from carma 1 (2-25) were amplified from genomic DNA by polymerase 
chain reaction (PCR) using JumpStart REDtaq ReadyMix (Sigma). Primers are listed in 
Appendix A. Typically PCR reactions were set up in 0.5 ml thin walled microcentrifuge tubes 
to a final volume of 50µl: 
 
 25µl JumpStart REDtaq ReadyMix (Sigma) 
 18µl H2O 
 5µl combination primer i.e. 2.5µl forward primer and 2.5µl reverse primer 
 2µl DNA made up to a concentration of 50ng/µl 
 
DNA amplification was performed using the following program: 
 
 
 
 
 
 
 
Table 4.2-1: Thermal Cycler program used for DNA amplification by PCR.  
 
Southern blotting was used to ensure amplification of a single PCR product: products were 
electrophoresed through 1% agarose gels at 120 volts for 35 minutes and then exposed to 
ultraviolet radiation for 90 seconds to confirm the presence of a single band. Where multiple 
bands were identified, the thermal cycling program was modified to improve PCR product 
Step Temperature Time 
1  94°C 2 min 
2a (genomic DNA separation) 94°C 30 seconds 
2b (primer annealing) 55°C 30 seconds 
2c (PCR product extension) 72°C 2 minutes 
3 72°C 5 minutes 
35 cycles 
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quality. Once PCR products for all carma1 exons were optimised, samples were purified by 
QIAquick PCR Purification Kit (Qiagen), sequenced (MRC CSC Genomics Core Laboratory, 
Imperial College London) and the data analysed with Sequencher software (Gene Codes 
Corporation).  
 
4.2.9 In vitro CD4
+ 
T cell activation and iTreg differentiation  
CD4
+
T cells were isolated from mouse spleen using magnetic beads (MACS
®
 technology) 
and activated for 48 hours with plate-bound anti-CD3 (1µg/ml) and anti-CD28 (2µg/ml) in the 
presence of rIL-2 (30U/ml) (eBioscience). Cells were then stained for CD25, CD62L, CD69 
and CD44 in order to assess the upregulation of an activated phenotype, defined as 
CD69
+
CD44
+
CD25
+
CD62L
low
, by flow cytometry.  To measure iTreg differentiation, 
MACS
®
 purified splenic CD4
+ 
T cells were sorted as naive CD4
+
CD25
-
CD44
lo 
cells
 
then 
stimulated with plate-bound anti-CD3 (0-10µg/ml) and anti-CD28 (1µg/ml) for 3 days in the 
presence of rIL-2 (100U/ml) and rTGF-β1 (2.5ng/ml) (Cell Signaling) and stained for FOXP3 
expression.   
  
4.2.10 Immunological assays 
4.2.10.1 Enzyme-linked immunosorbent assay (ELISA) 
Microtiter plates were coated with 50µl per well of single-stranded DNA in borate buffered 
saline (BBS) (10 μg/ml) then incubated for 3 hours at 37°C. After washing three times with 
phosphate buffered saline (PBS) containing 0.05% Tween-20, wells were blocked with 100µl 
0.5% bovine serum albumin (BSA) in PBS-Tween/NaN3 for 1 hour at room temperature. 
Homozygous Wt, Vulpo and Zerda mouse serum samples from 1 year old mice were prepared 
to 1/100 concentration in 2% BSA in PBS-Tween/NaN3. 2% BSA in PBS-Tween/NaN3 was 
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used as a negative control. Serum samples derived from an MRL/Mp.lpr/lpr mice pool were 
used as a positive control and prepared for a 12-point standard curve starting at 1/400 
concentration diluted in 2% BSA in PBS-Tween/NaN3. 50µl of each sample was added to 
each well and plates were incubated overnight at 4°C. The following morning, plates were 
washed five times in PBS and 50µl Alkaline phosphatase -conjugated goat anti-mouse IgG (γ-
chain specific) (Sigma-Aldrich) added to each well at a concentration of 1/3000, diluted in 2% 
BSA in PBS-Tween/NaN3. Plates were incubated for a further 4 hours at 4°C, washed five 
times with PBS and 50µl p-Nitrophenyl phosphate substrate (SIGMA) added to each well. 
Plates were read by spectrophotometer (Thermo Multiskan Ascent) at 405nm every 15 
minutes. Readings taken at 30 minutes provided an ideal standard curve and results were 
expressed as arbitrary Elisa units (AEU) relative to the standard positive sample derived from 
the MRL/Mp.lpr/lpr mice pool.  
 
4.2.10.2 Western blotting 
For Western blots, detergent extracts were resolved by 10% SDS-PAGE and 
electrophorectically transferred 
170
. The primary antibodies used were: rabbit mAb to 
CARD11 (1D12) (Cell signalling) and mouse mAb to beta ACTIN (Abcam). The secondary 
antibodies used were: polyclonal goat anti-rabbit immunoglobulin/HRP (Dako) and 
polyclonal goat anti-mouse immunoglobulin/HRP (Dako). Homozygous Wt, Vulpo and Zerda 
thymus lysates were run in duplicate. For immunoprecipitations (IP), MACS
®
 purified splenic 
CD4
+ 
T cells from 3 homozygous mouse spleens were activated in 1.5ml RPMI, phorbol 12-
myristate 13-acetate (PMA) (200ng/ml) and ionomycin (300ng/ml) for 6 hours at 37°C. Cells 
were harvested with PBS and lysed in 1ml RIPA buffer plus protease inhibitor cocktail 
(Sigma-Aldrich). Polyclonal rabbit anti-mouse Bcl-10 Ab (2µg) (Santa Cruz sc-5611) and 
protein A/G PLUS-agarose (20µl) (Santa Cruz sc-2003) were added to each 1ml sample (100-
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500 µg/ml total protein) followed by rotation at 4°C for 2 hours. Beads were washed 3 times 
with RIPA buffer, boiled in SDS loading buffer, resolved on 10% SDS-PAGE gels and 
Western blotted. Primary antibodies used were rabbit mAb to CARD11 (1D12) and 
polyclonal rabbit anti-mouse Bcl-10 Ab. For improved Western blotting detection to avoid 
heavy and light chain signals, blots were incubated with 1:5000 dilution of Protein A-HRP 
(Amersham) prepared in blocking buffer, in place of secondary antibody 
174
. 
 
4.2.11 Statistical analysis 
All results are given as mean values with SD. A nonparametric unpaired t-test (two-tailed) 
was applied: ***p<0.001, **p=0.001–0.01, *p=0.01–0.05, ns=not significant. All statistical 
calculations were performed using Prism5 software (GraphPad).  
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Appendix A: Carma1 primers used to sequence Carma1 in mutant and WT 
genomic DNA.  
 
Exon Forward Sequence Reverse Sequence 
non-coding TCATTTCGCATCACAACAAGCACTG TGGCAACCAGAGGTTTATTTCCAGG 
non-coding AGTGAACACAGAGCCCCAGTATGA TTCCATCTGGTGATGGCTCCTGA 
non-coding TGCTCAGTTAGAAGAAACAAGGAACCC CAGGTTCTGCTCAGAATAAAGCAAAAGG 
non-coding TCCAATGGATAAGCACTGCCTCCC GCGAGGTTGCTTTAGATGCTATCCC 
2 CTTATGCCAGGCAAACTGCACTTTC AGACAGAGACTCACTGCTCAGGAC 
non-coding CCAGAGCACAGTTGGTGACATGAAA AGAAAACTGACATGATAGTGTGTCCCTTG 
3 TGTATGGAACCTCTCACCCACACTC CCCCAATGACAGGACTTTCCATCTC 
4 GGCAGCCCAAGAGTTCAGCA ACACCATTTAAACCCCTCTGAATGAGAC 
5 AGGTCCCCTAACTTTCCATGAGCC GGGAACTAAGAGTTCAGTAAACGCTGC 
6 TGTGCCAACAGCATGGTTTGTAGTC GGCATTGCATGTGTCAGGAAATGG 
6 CTTTTCTCCCAGAGCTAGGGCATTG AGCTCAAGAATGACATCGAGAACCG 
7 ACGGTGGAGATACATCCTTGGTGG GGCTCAGTGTTCTTGAAGCAGAGAC 
8 GAATGCATCTCTGAGCTGGGGAC CATGAGCTAACTGTAGCCACTAAGCAA 
9 AAACAACACAGACACACATACAGACATACA AGACAGAAACAGGAGGATCATAAGCTCA 
10 TCCCTGGGTAGCAACCAAAGTGAC ACCCTGGAGATGGTATGAGCCAAG 
11 AGCATATACATGCGGGCATCACAC CCTGCCTCTCTGTGCTAATGGAAG 
non-coding GGAAGCCTTGCGTTATACTTCCACC TTCAGCCACAAACTCCTGGCTC 
12 TGTAACAGAAGGCTGGGACCCTAC ACACAAAAGTTGAGAGCCCCTGAAG 
13 CATGTTCAGATGACTCTGAGGCCG CCAAATCCAAGGTCCTGTTCCATCC 
14 GAGAGTGTGTCAGTGTCCCCAATG GCACCCTTCTGAACAGCTTAGACC 
15 AACTGATTTGTGACTGAGACTCTGGC TGTAGTAAGAGCTGTAGGGTTCTCACC 
16 ACCTTGTAATGCAGAGTGATGAGGC AGAGGACAGGGCGGTAGTTATTCC 
17 CTTGTAGCAGACTGGGAAGCATGAC GCACACAACTCTGAATGGCGATGG 
18 GGGCAGGATTGCAAGTTCAATTTTAGAC ACATTGTGGCTCAGCACAGATGTTAG 
19 & 20 ACCTGTCACTGCGGGGATAAAATG GCTCTCAGCCAATCAGATGGTCAG 
21 AGGGCTTCAGTCAATGTGGGCATC TCTGTGGGAACCTGGATTCTGTACC 
22 AACATTACGAGGTGGCCGAGTG GTTCAGCAGGTTTCTGAGACACCC 
23 TTGGGGAGTCACAGCTTGGAAAC TGGTCTGGCAGAGCAATCATGAAC 
24 GGTCAAGGACCACACATGACGG GTGAGTGTCCATTGCAAGCCCC 
25 ACTGTGCTTGATGGAAACACCTGC TCGAGCCCAAGAATGTAAGAAGCC 
 
  
  
 
120 
Appendix B: DNA isolation 
Tail clips were taken from 24 mice (12 from H2 offspring with mutant phenotype and 12 from 
H2 offspring with Wt phenotype). Clips were digested overnight by rotation at 50°C in 0.7ml 
lysis buffer and 70µl proteinase K (10mg/ml). Samples were then vortexed and 
hair/undigested debris precipitated by centrifugation for 15 minutes at 13,000 rpm. The DNA-
containing supernatants were transferred to clean tubes and 0.7ml isopropanol added to each 
sample, followed by mixing by inversion. Tubes were then spun at 13,000 rpm for 10 minutes 
to precipitate DNA pellets. Supernatants were discarded and DNA pellets washed with 0.5ml 
ice-cold 70% ethanol. Dry DNA pellets were then re-suspended in 350µl genomic DNA 
buffer and rotated overnight at 50°C to ensure complete DNA solution.  The DNA 
concentration of samples was calculated using a NanoDrop™ spectrophotometer.  
 
  
  
 
121 
Appendix C: List of single nucleotide polymorphisms (SNPs) used for 
genotyping Vulpo. 
 
No. SNP identity
1 01-034899657-N 45 06-122941044-M 89 01-159058371-M 133 04-068252469-M
2 01-050957023-N 46 07-022997618-M 90 01-165583809-M 134 04-081111774-M
3 01-082250512-N 47 07-042943665-M 91 01-178701443-M 135 04-088959560-M
4 01-089580704-N 48 08-093120105-M 92 01-185013929-M 136 04-097015585-M
5 01-144168459-N 49 08-123021323-M 93 01-191804699-M 137 04-103933951-M
6 01-172554503-N 50 09-003938578-M 94 02-004006715-M 138 04-109025153-M
7 03-065861493-N 51 09-053790242-M 95 02-012171555-M 139 04-116163539-M
8 03-124203459-N 52 09-084055613-M 96 02-020414303-M 140 04-127133018-M
9 03-144955281-N 53 10-003233934-M 97 02-026654160-M 141 04-141084977-M
10 04-014657884-N 54 rs3717445 98 02-030755750-M 142 04-145870512-M
11 04-075245266-N 55 10-103158653-M 99 02-038092910-M 143 04-151168886-M
12 05-065734378-N 56 10-123089825-M 100 02-043953410-M 144 05-009080098-M
13 05-115212503-N 57 11-024515722-M 101 02-050206336-M 145 05-015030133-M
14 06-036210417-N 58 11-044333996-M 102 02-056933273-M 146 05-023890459-M
15 09-033919969-N 59 11-054801294-M 103 02-064172278-M 147 05-030170202-M
16 10-042788082-N 60 11-084320332-M 104 02-074976198-M 148 05-039017415-M
17 11-005661856-N 61 12-113315003-M 105 02-078062303-M 149 05-044010971-M
18 11-063538723-N 62 13-023105764-M 106 02-101074874-M 150 05-050882266-M
19 11-095093300-N 63 14-093080383-M 107 02-104865091-M 151 05-069043957-M
20 13-043995023-N 64 17-013493244-M 108 02-119931810-M 152 05-078151229-M
21 13-052501751-N 65 17-073215081-M 109 02-124063590-M 153 05-084120220-M
22 13-065339791-N 66 18-005066417-M 110 02-139603599-M 154 05-091950247-M
23 14-031978791-N 67 18-084751134-M 111 02-167943959-M 155 05-097007418-M
24 14-042965786-N 68 19-025120427-M 112 02-175236812-M 156 05-100871112-M
25 14-060626617-N 69 12-018871120-N 113 02-179086475-M 157 05-107871207-M
26 14-112205439-N 70 12-067692873-N 114 03-011350737-M 158 05-128944450-M
27 16-064069423-N 71 12-107536049-N 115 03-026157475-M 159 05-136184664-M
28 17-086110517-N 72 01-007166135-M 116 03-032431792-M 160 05-149044358-M
29 17-092673068-N 73 01-014123597-M 117 03-037152198-M 161 06-008104124-M
30 18-063800148-N 74 01-022154835-M 118 03-053161686-M 162 06-015283563-M
31 19-045460279-N 75 01-029142332-M 119 03-059797081-M 163 06-020075608-M
32 01-043168343-M 76 01-058997955-M 120 03-073214161-M 164 06-028759322-M
33 02-113220302-M 77 01-065042402-M 121 03-081123258-M 165 06-045126062-M
34 02-133158154-M 78 01-069924080-M 122 03-098415492-M 166 06-050967077-M
35 02-152934935-M 79 01-077241287-M 123 03-110268748-M 167 06-058199906-M
36 03-104386660-M 80 01-086182722-M 124 03-138370314-M 168 06-076285738-M
37 04-022875524-M 81 01-094081544-M 125 03-152200034-M 169 06-090142535-M
38 04-043070534-M 82 01-102073421-M 126 03-158497808-M 170 06-095139289-M
39 04-122948823-M 83 01-110152038-M 127 04-008229128-M 171 06-101960309-M
40 04-132955150-M 84 01-116988763-M 128 04-030080285-M 172 06-115164803-M
41 05-003188964-M 85 01-124147455-M 129 04-037053163-M 173 06-128926170-M
42 05-143026004-M 86 01-132126870-M 130 04-046972984-M 174 06-136943848-M
43 06-062599520-M 87 01-137189321-M 131 04-053894587-M 175 06-146079591-M
44 06-083216741-M 88 01-152031524-M 132 04-061409675-M 176 07-006208019-M  
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177 07-009057918-M 221 09-111881261-M 265 13-077818021-M 309 18-043868444-M 353 rs13480578
178 07-018939701-M 222 09-118995402-M 266 13-084819885-M 310 18-078158450-M 354 rs13478808
179 07-028240185-M 223 09-125082704-M 267 13-091042598-M 311 18-090060367-M 355 rs29347820
180 07-029991530-M 224 10-014021037-M 268 13-101929792-M 312 19-018239318-M 356 rs29365622
181 07-036014647-M 225 10-019253812-M 269 13-107993079-M 313 19-031186563-M 357 rs3165748
182 07-048028246-M 226 10-027070647-M 270 13-113945175-M 314 19-038092479-M 358 rs4211507
183 07-057062790-M 227 10-045078228-M 271 14-004082624-M 315 19-051918908-M
184 07-064095712-M 228 10-053898997-M 272 14-011059049-M 316 19-058179075-M
185 07-071043704-M 229 10-092128703-M 273 14-016913520-M 317 X-008280846-M
186 07-078044642-M 230 10-094049193-M 274 14-024063411-M 318 X-036314320-M
187 07-085095955-M 231 10-107333522-M 275 14-029078879-M 319 X-054638016-M
188 07-092021090-M 232 10-115062433-M 276 14-046108187-M 320 X-068494838-M
189 07-099391547-M 233 10-129117100-M 277 14-054014360-M 321 X-088983890-M
190 07-106153798-M 234 11-011378766-M 278 14-067021276-M 322 X-111633440-M
191 07-114576068-M 235 11-019956728-M 279 14-074468555-M 323 16-005053446-C
192 07-118127386-M 236 11-039194893-M 280 14-077156430-M 324 16-012092571-C
193 07-124090029-M 237 11-047224208-M 281 14-099172131-M 325 16-019621494-C
194 07-129989877-M 238 11-070331570-M 282 14-108203728-M 326 16-025179119-C
195 08-004138223-M 239 11-077198334-M 283 15-004024569-M 327 16-031026287-C
196 08-011103791-M 240 11-091287860-M 284 15-010120073-M 328 16-037994236-C
197 08-017931675-M 241 11-108428031-M 285 15-017113859-M 329 16-045078790-C
198 08-022074356-M 242 11-115546745-M 286 15-022235389-M 330 16-049079612-C
199 08-028926710-M 243 11-122195777-M 287 15-030334445-M 331 16-056118825-C
200 08-035000451-M 244 12-009581325-M 288 15-038029796-M 332 16-066862514-C
201 08-041947937-M 245 12-016244499-M 289 15-044071932-M 333 16-075684315-C
202 08-047239384-M 246 12-026312484-M 290 15-051946000-M 334 16-090091107-C
203 08-054093936-M 247 12-029244061-M 291 15-057561875-M 335 16-096070057-C
204 08-075249544-M 248 12-034563785-M 292 15-074039561-M 336 X-123551831-M
205 08-088042210-M 249 12-041270227-M 293 15-081163423-M 337 02-145828186-N
206 08-098901421-M 250 12-048364436-M 294 15-088202966-M 338 02-160869410-N
207 08-107088585-M 251 12-054303300-M 295 15-094178941-M 339 02-069853291-N
208 08-114059240-M 252 12-061271925-M 296 17-007230139-M 340 03-131286062-N
209 09-008979920-M 253 12-074494300-M 297 17-027262193-M 341 03-017511270-N
210 09-016198772-M 254 12-081758527-M 298 17-035364626-M 342 03-088155864-N
211 09-020768402-M 255 12-084289638-M 299 17-042164456-M 343 05-120623301-N
212 09-027092605-M 256 12-092440423-M 300 17-048262313-M 344 06-107618320-N
213 09-040838924-M 257 12-099072867-M 301 17-056073815-M 345 07-014548611-N
214 09-048062033-M 258 13-009820324-M 302 17-065545592-M 346 08-069496369-N
215 09-061026505-M 259 13-015609597-M 303 17-080241937-M 347 08-080610993-N
216 09-067826343-M 260 13-030913320-M 304 18-013036555-M 348 11-102928307-N
217 09-076920055-M 261 13-037832161-M 305 18-019171445-M 349 15-101356293-N
218 09-089891382-M 262 13-047833889-M 306 18-022777507-M 350 17-022861830-N
219 09-097984353-M 263 13-060129254-M 307 18-030864114-M 351 18-049391366-N
220 09-105828528-M 264 13-071928027-M 308 18-037875535-M 352 18-070565016-N
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